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The potential benefits of using population isolates in genetic mapping due to reduced
genetic and environmental heterogeneity are offset by the challenges posed by these
populations for traditional association methods. Population isolates often contain large
amounts of direct and cryptic relatedness that confound baseline assumptions of
independence among genotypes and phenotypes and require specialized approaches to
account for this sample structure. We examined three such approaches for association
testing: (i) scoring allele transmission to offspring within families (ii) incorporating a
permutation-based association score between families into the test statistic and finally
(iii) incorporation of a kinship matrix to capture the relatedness among all individuals
into a mixed model to test for association. The mixed model approach had 88% power to
rank the true SNP as among the top 10 genome-wide top 10 with 56% achieving genomewide significance, a >80% improvement over other methods. We then used the mixed
model method for genome scans relating to metabolic traits and electrocardiographic
measures in 2,906 related individuals from the Island of Kosrae, Federated States of
Micronesia, who were previously genotyped for over 330,000 SNPs. We re-analyzed data
for 17 published and 8 previously unpublished metabolic and electrocardiographic traits.
We replicate seven genome-wide significant associations with known loci of plasma
cholesterol, high density lipoprotein, low density lipoprotein, triglycerides, thyroid
stimulating hormone and C-reactive protein, with only one detected in the previous
analysis of the same traits. We further report novel associations for height (rs17629022,
p<2.1E-8), homocysteine (rs7481043, p<1.3E-8) and uric acid (rs2186571, p<1.8E-34),
the latter two near relevant candidate genes. We demonstrated the increased power of
mixed-models for handling hidden and direct relatedness in isolated cohorts and
discovered three novel associations with height, homocysteine and urate levels. Our
experiences in association testing in an isolated population can serve as a model for other
studies of similar cohorts
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Chapter 1 : Introduction

Genome-scale human genetics in 2010

Rapid technological advances have accelerated the pace of human genetics in the past
decade. Landmark accomplishments include the initial sequencing of the human genome
in 2001 (Venter, 2001, Lander, 2001) and the completion of a “finished-grade” human
genome reference sequence in 2004 (The Human Genome Project, 2004). Another
landmark achievement was the release, in 2005, by the HapMap Consortium, of the first
phase of an international effort to discover and expand the catalogue of human single
nucleotide polymorphisms (SNPs). As a result, by August 2006, there were more than ten
million SNPs in the National Center for Biotechnology SNP database (dbSNP), and
examination of the HapMap SNP‟s, derived from four populations across three
continents, revealed ~2M of them to be commonly polymorphic (The HapMap
Consortium, 2005).

These advances made possible the development of genome-scale genotyping platforms
(“SNP chips”), which could, at a reasonable cost, assay 100K-1M common polymorphic
genotypes across hundreds to thousands of individuals (Hirschhorn, 2005). These “SNP
chips” were utilized for the design of genome-wide association studies (GWAS), in
1

which a dense set of SNPs across the genome is used to survey the most common genetic
variation for a role in disease or to identify the heritable quantitative traits that are risk
factors for disease. The underlying rationale for GWAS is the „common disease, common
variant‟ hypothesis, positing that common diseases are attributable in part to alleles
present in > 5% of the population (Reich, 2001). To achieve unbiased association signals,
GWAS are mainly performed in cohorts of unrelated individuals, following a case/control
design, a departure from decades of traditional variant discovery that relied on heritability
within families. The first GWAS emerged in April 2005 (Klein, 2005), and to date,
GWAS have reproducibly implicated over 700 genomic regions that modify the risk for
over 120 complex disease and health-related phenotypes (Kruglyak, 2008, Manolio,
2008).

Taken together, this ongoing data bonanza has opened the window to myriad previously
unknown variation in the human genome, and a current challenge in human genetics is to
identify the specific variation that increases susceptibility to diseases.

Complex disease gene mapping

Human geneticists seek to understand the inherited basis of human disease and the
underlying biology that contributes to disease pathophysiology. The goal is to gain
clinical insights that could eventually improve treatment, produce useful diagnostic or
2

predictive tests, and to gain biological insights that could help elucidate the functional
mechanisms underlying disease. Compared to rare Mendelian (or “monogenic”) diseases,
complex (or “polygenic”) diseases (such as cancer, coronary artery disease and diabetes),
or their underlying quantitative phenotypes (such as lipid levels and blood pressure),
occur fairly commonly in human populations (see Figure 1.1). A substantial portion of
individual differences in complex disease susceptibility are known to be due to genetic
factors, however effects of age, gender, lifestyle, other environmental covariates, and the
interactions between them, are also known to play a role.

Detecting variants effecting complex disease

The small genetic contribution of individual
genes, combined with the confounding effects
of non-genetic factors on phenotype measures,
have meant that loci affecting complex diseases
have been historically difficult to detect, with
only a handful of examples prior to 2005 (for
example,

the

APOEε2/ε4

polymorphisms

affecting cholesterol levels and Alzheimer‟s
disease (Zannis, 1981).

However, with the

advent of GWAS undertaken in a large number
Figure 1.1: Schema comparing Mendelian
(“monogenic”) and complex (“polygenic”)
traits.

3

of samples, many novel and convincingly associated loci have been mapped to numerous
common polygenic disease and quantitative traits, for example, at least 32 loci for
Crohn‟s disease and 95 loci for plasma lipid levels (McCarthy, 2008, Burnett, 2008, pers.
comm. Sekar Kathiresan).

Examination of the emerging loci have revealed some interesting biological insights. On
one hand, GWAS have implicated many genes that had prior evidence from candidate
gene studies to play a role in their respective traits. For example, of 23 loci found to be
associated with lipid levels in one study, 11 implicate genes encoding apolipoproteins,
lipases and other key proteins in lipid metabolism pathways (Mohlke, 2008). Further,
>20% of loci discovered in GWAS for a variety of complex traits are known to also
harbor mutations that cause monogenic diseases (Hirschhorn, 2009). On the other hand,
GWAS have highlighted pathways whose relevance to a particular disease or trait was
previously unsuspected, such as autophagy and interleukin-23-related pathways for
Crohn‟s disease and the complement system for age-related macular degeneration, and
this clustering into pathways is highly non-random (Raychaudhuri, 2009).

Most of the time, the causal variant driving a GWAS signal is not the SNP directly
assayed, but an unknown variant in the vicinity of the measured SNP, which is tagged by
that SNP by virtue of residing on the same haplotypic background (being in “linkage
disequilibrium” (LD)). Therefore, detecting a GWAS signal is merely the first step
4

toward discovering the underlying causal variant and various approaches can be taken to
fine map the signal. One conventional approach is sequencing a region of arbitrary length
around the signal peak across enough individuals to capture the causal allele. However,
the larger the sequenced interval and number of individuals, the more variants
discovered, making it difficult to distinguish the driver allele from the large number of
passenger variants. This problem is exacerbated in cases where multiple, seemingly
independent signals reside in close proximity along the genome (Haiman, 2007, Yeager,
2007, Gudmundsson, 2007, Fellay, 2007, Duerr, 2006, Barrett, 2008, Romeo, 2008,
Graham, 2007, Graham, 2008, Abelson, 2009, Plenge, 2007). Studies to identify the
culprit causal variant(s) underlying the local peaks in association signals have shown
mixed success, with only handful of causal variants identified so far (Burnett, 2008,
Moffatt, 2007, Burkhardt, 2008) and many re-sequencing efforts proving unsuccessful
(Lowe, 2007, Burfoot, 2008, Hafler, 2009). One possible explanation may be that the
GWAS signal is driven not by a single common causal variant, but by multiple effects of
rare variant in a synthetic association with common alleles assayed in the GWAS
(Dickson, 2010).

A limited fraction of heritability is captured by common variants

Thus far, almost all GWAS discovered signals, both individually and in combination,
have exhibited modest to small effects on their associated traits (with a few notable
exceptions, such as age-related macular degeneration (Klein, 2005) and drug induced
5

liver injury (Daly, 2009). In fact, most traits examined so far in GWAS explain <5% of
the fraction of heritability of that trait (Hirschhorn, 2009). A recent very well-powered
GWAS of > 100K individuals for lipid levels, that expanded on a previous study with
30K individuals, yielded ~65 extra loci, but added only 1-2% to the total fraction of
heritability explained for the trait (Kathiresan, 2009, pers. comm. Sekar Kathiresan).
Further, there has been a scarcity of detected reproducible associations for some
examined traits, especially neurological disorders, despite numerous GWAS efforts (Liu,
2010, McMahon, 2010, Garriock, 2010).

Many explanations to account for the source of this missing heritability have been
suggested, including rare and/or structural variants, poorly captured by current GWAS
platforms, gene-gene interactions, high signal-to-noise ratio in current GWAS strategies,
the affects of environment in study populations, and“hidden” epigenetic effects (Manolio,
2009). In response, the community is developing broader strategies for measuring such
effects, for example, genome-wide analysis of epigenetic markers (Laird, 2010), a new
generation of SNP chips (aided by the 1,000 Genomes Project) and tiling arrays targeting
common and rare markers and structural variants, respectively, re-sequencing and
sequencing-based population studies. Consensus is currently lacking, however, on which
approaches and priorities for research will be most fruitful for pinning down the causes of
the missing heritability.

6

Designing improved causal variant discovery approaches

In designing improved approaches for discovering causal variants that contribute to
complex disease, a number of considerations must be taken into account, such as:
optimizing power for discovery, the expected impact of findings to the field and finite
research dollars. The ideal strategy, therefore, would balance cost-effective, genomescale analysis with generality to different populations and multiple traits. In addition, the
goal would be to redirect emphasis from discovering common, ancient variation (the
target of current GWAS in outbred populations) to exploring rare or unique, newly arisen
variants. To this end, renewed focus has been placed on study populations that play to
these strengths and have been historically used for traditional genetic approaches, namely
founder populations (Manolio, 2009).

Founder populations in gene mapping

Populations that have a small number of founders and/or are geographically or culturally
isolated from other populations (“founder” or “isolated” populations) have a long history
in genetic mapping studies of inherited disorders, particularly for the identification of
rare, monogenic disease mutations (Arcos-Burgos, 2002, Heutink, 2002). Genetic
isolates, such as the Finnish, Icelandic, Costa Rican, Old Order Amish, Jewish, Hutterite
and Sardinian communities, have been successful in mapping not only rare monogenic,
7

but complex traits (Ober, 2001, Angius, 2002, Peltonen, 1999, Gulcher, 2001, Freimer,
1996, Zamel, 1996, Abney, 2000, Aulchenko, 2004, van der Walt, 2005).

Founder populations share a specific set of features as compared to outbred populations,
namely reduced genetic diversity, reduced genetic and environmental heterogeneity, and
often large, multi-generational pedigrees. The resulting reduction in allele heterogeneity
has contributed to the success of genetic linkage and positional cloning approaches in
isolated, founder populations (Peltonen, 1999, Gudmundsson, 2002, Lindqvist, 2000).
These same properties that make isolated populations valuable for Mendelian trait
genetics may be exploited for gene mapping of complex traits. Here we investigate the
advantages and limitations of exploiting homozygosity in isolated populations for
analysis of alleles affecting complex traits (Peltonen, 2000, Heutink, 2002, Gulcher,
2001).

Advantages of using founder populations in complex trait mapping

Genome-wide association studies (GWAS), performed in outbred populations, have thus
far identified many common variation contributing to complex diseases (Hindorff, 2009).
One limitation in these studies is that rare variants that are not in linkage disequilibrium
with the common variants assayed are usually not detected (Bodmer, 2008). However,
when the populations analyzed in a GWAS have a substantial number of individuals that
8

share a recent common ancestor, not only common variants (Lowe 2009, Wang 2009),
but sometimes also rare variants appearing at a higher frequency, or within a discernable
haplotype structure, can be identified (Sabatti, 2009, Pollin, 2008, Kallio 2009). Further,
while multiple rare mutations may segregate in an outbred population, founding events
and subsequent population bottlenecks may reduce the allelic diversity such that a single
mutation dominates the allelic spectrum in an isolated population.

Founder populations typically exhibit a large amount of direct and cryptic relatedness, as
compared to outbred cohorts, and this high degree of relatedness may result in increased
homogeneity in phenotypes. In the case of small population isolates, well-documented
multigenerational pedigrees can often be constructed, facilitating longitudinal analysis of
both phenotypes and genotypes. Population isolates may also share similar environments,
decreasing the signal-to-noise ratio for mapping. Finally, isolated populations often
exhibit relatively high amounts of inbreeding producing an increased incidence of
recessive phenotypes which are difficult to detect in outbred populations (Peltonen,
2000).

Technical challenges

Inbreeding and the historical lack of random mating in founder populations violate
assumptions of independence between genotypes and phenotypes confounding classical
9

association tests which measure the frequencies of alleles in disease cases versus
controls. Specialized tests may account for any “known” relationships in the population,
however hidden (relationships unreported or incorrectly specified) or cryptic relatedness
(unreported or unknown distant relationships) may confound even specialized test
statistics. Further, since consanguinity may be present, two alleles in a random individual
may also be correlated. The hidden correlation in the data can cause an overdispersion in
the null distribution of the naïve test scores for association and consequently, false
positive associations. Hence, the major challenge for performing GWAS in isolated
populations is to account for this non-random intra- and inter-individual correlation.

Most GWAS have been thus far focused on outbred populations, and >75% utilize
populations of European descent exclusively (Rosenberg 2010). This can lead to
additional analytically challenges when studying non-European and/or founder
populations. Several studies have found that markers typically used in GWAS are in
various ways non-random (Nielsen 2004, Clark 2005). The focus on SNPs with high
minor allele frequencies in populations of European ancestry in the initial selection of the
markers for use on current GWAS platforms, in turn affects the relative proportion of the
genome suited to mapping in different populations. This problem is exacerbated in
founder populations, where the reduced genotypic heterogeneity further decreases the
number of viable markers.

10

A recent trend for increasing power in GWAS is to adopt a genotype-imputation strategy
(Halperin 2009). The approach relies on the assumption that two haplotypes, that are
identical for a set of nearby markers, are likely to share the intervening chromosomal
stretch identically by descent. Therefore, if one of the two haplotypes is genotyped more
densely than the second haplotype, genotypes at the unmeasured positions on the second
haplotype can be predicted (“imputed”). This approach requires the availability of a
densely genotyped reference panel, such as the HapMap project (Frazer 2007). However,
there is reduced portability of this approach to populations that are, compared to available
reference panels, genetically distinct, such as founder populations. This leads to a
reduction in imputation accuracy, and a consequent reduction in statistical power for
imputation based association mapping.

To take full advantage of the opportunities afforded for detecting causal variants in
founder populations, there is a clear need for improved methods to overcome these
technical challenges. To tackle this problem, we studied two distinctly different founder
populations; a small, island-based, extreme isolate (the Kosrae islanders) and a large,
urban-based, less extreme founder population (the Ashkenazi Jews).

11

A small, extreme founder population: Kosrae

Kosrae is a Pacific Island member of the Federated States of Micronesia. It is located in
the Pacific Ocean 370 mi (590 km) north of the equator, between Guam and the Hawaiian
Islands, at 5°17‟ north and 162°58‟ east, longitude and latitude. Its land area is very
small, approximately 42 mi2 (110 km2) and the current day population of the island is
~7,700 according to the most recent 2001 census.

The history of Kosrae

Although no historical records exist, it is believed that Kosrae was originally settled by a
small number of founders (estimated to be 50) between 1,500-2,500 years ago, and
subsequent estimates of the founder population size from current day genetic data from
Kosrae support this (pers. comm. Dr Itsik Pe‟er and Sasha Gusev). Recent work has
suggested that the island settlers were Polynesian, originally of aboriginal Taiwanese
descent (Friedlaender, 2008, Kayser, 2008). Kosrae was first sighted by Westerners in
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Figure 1.2: Estimates of population size for the past 2,500 years on the Microneasian Island of
Kosrae

1804 and first visited in 1824. During the 19th century, the combined effects of a typhoon
(in 1835) and exposure of the native population to Western communicable diseases
reduced the indigenous population from greater than 3000 to around 300 individuals by
1888. Historical and genealogical records also indicate that there was admixture between
native Kosraean females and 4-6 male Caucasian whalers from New England and Europe
who visited the island in the mid to late 19th century. However, current day estimates of
Caucasian admixture on the island indicate that there is an average <1% Caucasian
genome across all the islanders (Bonnen, 2010).
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Spain originally claimed Kosrae, but the island was purchased by Germany in 1899
following the Spanish-American War. After World War II (WWII), the Federated States
of Micronesia, including the islands of Kosrae, Truk, Yap, and Pohnpei, became a
protectorate of the US government. At that time, the island population was estimated to
be 1,550.

A diet shift on Kosrae

Figure 1.3: Representation of the diet of indigenous Kosraens pre- (to the left) and post- (to the
right) WWII. Pre-WWII, the indigenous islanders diet was high in starch (from tubers and fruit) and lean
proteins (from fish) and polyunsaturated fats (from nuts). Post-WWII, with the supply of ready-to-eat meals
from the US, the diet shifted to a high salt, high fat diet.

A number of visitors to the island in the 19th and early 20th century noted the natives to be
thin. Prior to WWII, the Kosraens consumed a diet consisting mostly of fish, fruits and
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vegetables. The designation of Kosrae as a US protectorate led to a drastic life style
change on the island. Kosraens no longer had to fish for sustenance and assumed a more
sedentary lifestyle. In addition, the diet on the island changed to a more Western diet with
large quantities of high fat foods supplied through US aid (such as Spam, turkey tails,
hamburgers, and ice cream). These changes resulted in a dramatically increased
prevalence of obesity, an outcome similar to that seen in other indigenous populations
exposed to a Western diet and lifestyle, such as the Samoans of Polynesia and the Navajo
Native Americans of southwestern United States (Schumacher 2008, Lee 2008).

The current health status of the islanders

In response to the apparent growing epidemic of obesity on Kosrae, the United States
Department of Health conducted a survey of the Island in two screenings in 1994 and
2001. They collected information on a range of clinical traits that underlie the Metabolic
Syndrome—a

co-occurrence

of

metabolic abnormalities that groups
together multiple traits that comprise

Table 1.1: Incidence of Metabolic Syndrome,
Obesity and Diabetes on Kosrea as compared to the
US. Estimates are based on guidelines from 1,2,3Third
Report of the National Cholesterol Education Program
Expert Panel on Detection, Evaluation , and Treatment
of High Blood Cholesterol in Adults 2003-2006.

serious risk factors to type 2 diabetes
(5.8% prevalence in the US), coronary
artery disease (4.8% prevalence and
the leading cause of death in the US),
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stroke (1.6%) (Ervin 2009). These outcomes therefore have a significant negative impact
on population health in developed countries.

Prevalence estimates of metabolic syndrome were calculated for both 1994 and 2001
health surveys and were found to be very high, rising from 27% in 1994 to 42% in 2001,
a surge of more than 50% in a seven year span. Comparisons to other regions of the
world show that Kosrae has one of the highest recorded rates of metabolic syndrome;
roughly 3-, 4- and 2-fold higher than estimates for Koreans, Japanese and the United
States, respectively (see Table 1.1) (Cameron 2004).

A large, less extreme founder population: Ashkenazi Jews

The Ashkenazi Jewish people (AJ) represent a founder population with a distinct wellchronicled history. Although the AJ and Kosraen populations were both founded at a
similar time in history, the two populations differ in many of their features. The AJ
population is linked not by geographical isolation, but rather by: religion, language,
customs and the traditional practice of endogamy. These practices have resulted in a
distinct AJ genetic identity that has persevered despite thousands of years of migration
and the physical separation of different AJ communities.
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The history of Ashkenazi Jews

The Jewish people originated in the Middle East around the first millenium before the
Common Era (BCE) and have had a long history of migration throughout the Middle
East, North Africa and Europe, and more recently the Americas, Australia and South
Africa. According to their area of long term residence, the modern Jewish people are
divided into three groups; Sephardic Jews (who resided in Spain and Portugal until the
15th century), Middle Eastern Jews (who lived in contemporary Palestine and Israel, as
well as Iraq, Iran and other Middle Eastern countries) and Ashkenazi Jews (who lived in
Western and Eastern Europe).

The Ashkenazi Jews (AJ) moved into Europe and then over the Alps into the cities of the
Rhineland around the 9th century, where they developed their own language (Yiddish).
During the 12th and 13th centuries, the AJ were expelled from the Rhineland, and resettled
in Eastern Europe, mainly Poland, Lithuania and Russia. In the late nineteenth and early
twentieth centurys, there were large AJ migrations westward (to America and Western
Europe) and southward (to Australia and South Africa). Two important events in the
twentieth century brought about the depletion of Jewry in Europe; the Jewish Holocaust
of the WWII, which lead to the death of 6 million Jewish people and migration out of
Europe, and the foundation of the state of Israel and the subsequent migration of Jews
from all over the world to Israel.

17

Contemporary Ashkenazi Jews comprise ~13 million people, with the largest
demographic centers being the United States (US), primarily the New York metropolis,
and Israel where 5-6 and 3-4 million Jews reside, respectively. Around 90% of New York
based Jews are of Ashkenazi descent, making Ashkenazi Jews the largest founder
population in the United States.

Ashkenazi genetic identity

By Jewish religious law, Jewish identity follows matrilineal inheritance. However,
studies of mitochondrial and Y-chromosomal polymorphisms provide strong evidence for
both maternal and paternal transmission, supporting historical evidence for many
generations of endogamy in this population (Ostrer, 2001). Further, studies of maternally
inherited mitochondrial DNA have suggested that most Jewish communities were
founded by relatively few women (Thomas, 2002), and that almost half the modern AJ
population may be descendent from just four women (Behar, 2006).

Since the middle of the 20th century however, many Ashkenazi Jews have intermarried,
both with members of other Jewish communities and with people of other nations and
faiths, while some Jews have also adopted children from other ethnic groups or parts of

18

19

the world and raised them as Jews. Conversion to Judaism, rare for nearly 2,000 years,
has become more common. Nonetheless, it has been shown that self-described Jewish
ancestry is a major determinant of population genetic structure in European populations
(Price 2008) and a recent study has shown that AJ individuals with different amount of
AJ ancestry can form distinct identifiable groups based on genetic data alone (Need
2009).

Contemporary Ashkenazi Jewish populations have been studied extensively by the
medical genetic community where at least 40 genetic conditions have been dissected
(Ostrer 2001). Some of the mutations are found in multiple Jewish groups, such as the
common mutation in the BRAC1 gene which increases susceptibly to cancer, which is
likely to have originated before the dispersion of Jews (Bar-Sade 1998). However, in
many cases the mutations are likely to have risen during migration and/or bottleneck
events, where one or two prevalent founder mutations have occurred, for example,
mutations in the GBA and the LDLR genes which cause Gaucher disease and
hypercholesterolaemia, respectively (Diaz 2000, Durst 2001).

Crohn’s disease in Ashkenazi Jews

Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract,
which is thought to result from the effect of environmental factors in a genetically
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predisposed host. An epidemiological feature of CD is that it has highest prevalence
among individuals of AJ descent, occurring two to four times more frequently than in
non-Jewish Caucasian populations. Three coding variants of the NOD2 gene have been
reported as independent disease-predisposing mutations for CD. Confirmation studies
have shown, however, that these susceptibility loci have similar allele frequencies and
magnitudes of the effect and are unlikely to contribute to the excess prevalence of the
disease in the AJ population. Therefore, involvement of other, yet unknown, genetic
variants unique to this population is hypothesized.

Improving methods for genome-scale genetics in founder populations

The focus of my thesis was the development of new, optimally-powered strategies for
analysis in founder populations. I started with the genome-scale genetic analysis of an
extreme founder population, the Pacific Island of Kosrae. Analysis of this population
(ongoing when I joined the Breslow lab in the summer of 2006) using existing methods
had demonstrated reduced power in this cohort as compared to a similarly sized outbred
cohort (Lowe, 2009).
The primary goal of my thesis was to develop improved strategies for causal variant
detection on Kosrae. We had previously shown abundant long genetic segments shared
identically by descent on the island (Bonnen, 2006). Taking advantage of these long
haplotypes, we developed a method for mapping causal haplotypes under a GWAS local
signal peak (see Chapter 2) for dissecting multiple signals at the same locus, and
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elucidated a putative causal variant. Next, we evaluated four specialized methods for
performing GWAS in the context of relatedness using extensive genome-scale
simulations (see Chapter 3), and demonstrated that mixed-models are best powered for
these populations, Finally, leveraging these optimized strategies we performed a GWAS
of 30 traits pertaining to metabolic disorders on Kosrae (see Chapter 4), reporting 10
positive controls and 3 novel findings, one of which was refined by a factor of 4 with
haplotypic mapping.

The secondary goal, of my thesis was to determine whether analysis methods developed
on Kosrae, could be utilized for the analysis of a less extreme founder populations, such
as the Ashkenazi Jews. To demonstrate this, we performed a combined-analysis of seven
Ashkenazi cohorts (see Chapter 5) and used mixed-models to perform a GWAS for
Crohn‟s disease. We report two positive controls and one novel finding, where haplotypic
mapping at one of the loci dissected two independent signals.
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Chapter 2 : Materials and Methods

Kosrae study population collection

The data collection and phenotype definitions on the island of Kosrae is explained in
detail in Lowe et al 2009 and Kenny et al 2010 (Lowe 2009, Kenny 2010). The screen
was carried out by Steven Auerbach of the US Health Department, Maude Blundell of the
Starr Center for Human Genetics at the Rockefeller University, and Vita Skilling of the
Kosrae hospital, as well as the medical staff on the island of Kosrae.

Briefly, we

surveyed 3,148 highly-related individuals from the Pacific Island of Kosrae in three
separate screenings carried out in 1994 , 2001 and 2003 which represent >75% of the
adult population on the island. All participants signed the informed consent prior to
filling out questionnaires about medical and family history, physical examinations and
blood drawings. Each person was assigned a unique identification number and filled out a
questionnaire which noted the participant‟s sex, family data including listing of biological
parents, siblings, and children, smoking status, alcohol intake, medications (the island has
a limited formulary), self-reported ethnicity, age, and health status. The family data was
used to derive the parity status of the women (0 to 5 and ≥6 children). Finally, village of
residence was recorded, where all individuals resided in one of five villages (Lelu,
Malem, Tafunsek, Utwe and Welung).
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Measuring phenotypes pertaining to Metabolic Syndrome and cardiovascular
conductance on Kosrae

In all three screens, fasting blood was collected and centrifuged. Plasma and buffy coats
were frozen and shipped to Rockefeller University, NY, for serological assays and DNA
extraction. Phenotypes were measured for 30 metabolic and electrocardiographic traits;
height (HGT), weight (WGT), waist circumference (WST), body mass index (BMI),
percent body fat (PCF), leptin hormone levels (LEP), fasting blood sugar (FBS), insulin
sensitivity (INS), Non-Insulin-Dependent Diabetes Mellitus (NIDDM), systolic blood
pressure (SBP), diastolic blood pressure (DBP), total choleseterol (TG), low density
lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglyceride
(TG), Lipoprotein(a) (LPA), Campesterol (CAMP), Sitosterol (SITO), Lathosterol
(LATH), C-reactive protein (CRP), thyroid stimulating hormone (TSH), glomular
filtration rate (GFR), homocysteine (HOMO), folic acid (FLT), uric acid (URT), QT
interval (QT), PR interval (PRD), QRS interval (QRS), Sokolow-Lyon voltage (SLV),
Cornell voltage (CLV) and RR (inverse heart rate) interval (RRD).

Anthropomorphic, Obesity, Diabetes and Hypertension:

HGT (cm‟s or inches converted to cm‟s), WGT (lb‟s or lb‟s converted to kg‟s) and WST
(cm‟s of inches converted to cm‟s) were measured for males age 24-80 and females age
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22-80 who were considered to have reached their full adult height and weight. Individuals
measured for HGT in more than one screening were omitted if their measurements
differed by more than 4 cm‟s. BMI was calculated as WGT (kg) divided by HGT squared
(m2). Obesity was defined as a BMI ≥30. PCF was measured using custom equipment
(the “BodPod”, Tanita manufacturing company, Tokyo). FBS (mg/dL) was measured by
fingerstick with a glucometer and pre-NIDDM and NIDDM were defined according to
the American Diabetes Association (ADA) recommendations as impaired fasting glucose
(FBG 100-125 mg/dL) or impaired glucose tolerance (GTT 140-199 mg/dL) and FBS 
126 mg/dL or OGTT2  200 mg/dL, respectively. Individuals under treatment with
insulin or oral hypoglycemic drugs were excluded. The average of three seated SBP
(mmHg) and DBP (mmHg) measures, taken manually with a stethoscope and
sphygmomanometer, for individuals aged 20-75, was used in the analysis. Treatment for
hypertension was taken into account by calculating an adjusted residual based on (Levy
2000).

A venipuncture was done for determination of serum levels of steroid hormones, lipids
and other biomarkers. LEP levels (ng/mL) were determined using commercial
radioimmunoassay (ELISA) in the Freidman Lab by Jeffery Winick, The Rockefeller
University, NY, (Diagnostic Systems Laboratories, Webster, TX and Linco Research Inc,
St Charles, MO). INS concentrations were measured on 740 randomly selected samples
using a sensitive enzyme-linked immunosorbent assay (ELISA), at Graeme Bell‟s lab at
the University of Chicago (Hartling 1985).
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Lipid levels

TC (mg/dL) and TG (mg/dL) were measured either in the Breslow Lab, The Rockefeller
Univeristy, NY, with commercially available enzymatic kits (Boehringer Manheim,
Indianapolis, IN, Sigma Diagnostics, St. Louis, MO) or in the Rogosin Institute, NY, on a
Roche COBAS Integra clinical chemistry analyzer using an enzymatic method, for the
1994 and 2001/2003 screens respectively. For the 1994 screen, LDL and HDL
quantification was not possible due to the lack of an adequate centrifuge on the island and
the inability to ship serum overnight at 4 C. As substitutes, the major apolipoproteins of
LDL and HDL (APOB (mg/dL), and APOA-I (mg/dL), respectively) were measured
using a standard double antibody immunoassay technique at Linda Youngman‟s lab at the
Oxford University. Both APOB and APOA-I are highly correlated with their respective
cholesterol fractions, making them excellent surrogates (Bachorik 1997). For the
2001/2003 screen, HDL (mg/dL) was also measured in the Rogosin Institute on a Roche
COBAS Integra clinical chemistry analyzer using an enzymatic method, and LDL
(mg/dL) was calculated using the Friedewald formula (Friedewald 1972):

LDL (mg/dL) = TC(mg/dL) – HDL(mg/dL) – TG(mg/dL)/5

For individuals with a triglyceride value >400 mg/dL the LDL value was set as missing.
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Plasma plant sterol levels (CAMP (mg/dL) , SITO (mg/dL) and LATH (mg/dL)) were
measured by gas liquid chromatography (Heinemann 1993) in the Seyhayek Lab, The
Cleveland Clinic, OH, and plasma levels of CAMP, SITO and LATH were expressed as
the ratio of sterol to total plasma cholesterol levels. LPA levels (mg/dL) were measured
in the Rogosin Institute, NY, using the Polymedco assay (which is not sensitive to the
Lp(a) Kringle IV type 2 repeat size polymorphism).

Biomarkers

TSH levels (IU/ml) were measured in the Rogosin Institute, NY. CRP (mg/dL) was
measured using a chemiluminescent immunometric assay (Immulite 2000 High
Sensitivity CRP, DPC, Los Angeles, CA) by the Rogosin Institute, NY. Positive outliers
(>3 SD corresponding to >27.4 mg/L) were considered acute inflammatory reactions and
excluded (n=28). All values below the functional sensitivity level of the assay (0.02)
were Winsorized to 0.02 (n=36). Direct measures of GFR were not made for Kosrae
subjects, and instead were based on plasma Creatinine (mg/dL) measured in the Rogosin
Institute, NY, according to the widely used Modification of Diet in Renal Disease
(MDRD) Study formula adjusted for a Chinese cohort:

GFR=229 × Creatinine(mg/dL)-1.154 × Age(years)-0.203 (× 0.742 if female)
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Individuals with GFR < 60 mg/dL (n=52) were considered “affected” for kidney disease
and excluded. HOMO, URT, FLT levels were all measured in the Rogosin Institute, NY.
Individuals taking diuretics (n=27) were excluded from the analysis of URT.

Electrocardiographic measures:

During the 2001 screen, twelve-lead electrocardiograms were recorded at a paper speed
of 50 mm per second in 1756 individuals using a Universal ECG (QRS Diagnostic LLC,
Plymouth, MN). De-identified paper electrocardiograms were scanned at high resolution
using a Hewlett Packard 2840 All-in-one into digital images. Quantitative measures of
QT interval (ms), RR (inverse heart rate) interval (ms), QRS duration (ms), PR interval
(ms), P wave duration (ms), SLV (mV), CLV (mV) and PQ interval (ms) were obtained
using digital calipers in Rigel 1.7.3 (AMPS LLC, NY) from two cardiac cycles of lead II
and one cycle each from V1-V5 (approximately orthogonal vector components). PR
interval was measured from the onset of the P wave to the onset of the QRS complex and
PQ interval from the offset of the P wave to the onset of the QRS complex. SLV was
determined from the sum of the amplitude of the S wave in lead V1 and the R wave in
lead V5 and CLV from the sum of the amplitude of R wave in a VL and S wave in V3.
The QT interval is measured from the earliest onset of the QRS complex to the end of the
T wave (in leads II and V5) and the RR interval is the R wave to R wave interval, and is
the inverse of the heart rate.
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Trait covariate and normality adjustments

Statistical analysis was carried out using the JMP package (SAS Institute Inc., Cary, NC).
All phenotyped and genotyped individuals between the ages of 18-88 were included in
the analysis except where indicated above. All traits were separated by gender, adjusted
for the effect of age (an adjusted residual based on age binned in 5-year intervals),
outlier‟s ≥3 standard deviations from the mean were removed and Z-scores were
calculated for each group. Pregnant women and non-Kosraen individuals were excluded.
For monozygotic twins and individuals screened twice/thrice, the average Z-score was
used. For some traits, the effects of additional covariates (BMI, smoking, village etc)
were evaluated using either univariate logistic regression or multivariate logistic
regression analysis to evaluate the effects of single or multiple covariates together,
respectively, and the trait adjusted accordingly. Z-scores may be log or square-root
transformed for normality. Finally, Z-scores were pooled across groups for downstream
analysis.

Genotyping and quality control

2,906 study participants were successfully genotyped on the Affymetrix 500K platform;
data were generated at Affymetrix, South San Francisco, CA. Genotypes were called with
the BRLMM algorithm and a minimum call rate of 95% was achieved. 446,802 SNPs
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passed quality control filters and between ~122K-91K SNP‟s that were monomorphic or
very rare (minor allele frequency (MAF) < 0.010 for each phenotype were also excluded.
The final dataset yielded between 354,901-323,902 SNPs per phenotype with MAF >
0.01 for the analysis.

Pedigree construction

A first pass reconstruction of the extended pedigree of the 3,000-strong cohort included
denser sampling of a further ~1,000 related non-genotyped individuals to fill out the
pedigree and careful cross-referencing of patient records. The extended Kosraen pedigree
spans eight generations including 4,300 people (living or deceased), where ~90% of the
individuals are contained in a single very large kindred. Genome-wide SNP data were
subjected to identity-by-state analyses and identity-by-descent estimation performed in
PLINK (Purcell 2007) to correct and validate the pedigree structure. Full details of the
pedigree construction are described elsewhere (Lowe 2009). The CraneFoot pedigree
drawing software was used to visualize subsets of the extended pedigree.

Kosrae trait heritability estimates

Prior to undertaking a complete genome scan, to ensure that there were genetic factors
involved in the quantitative traits under study, heritability (h2) was calculated. h2 is a
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measure of the percentage of the variance in the trait that is attributable to the additive
effects of genes, and is calculated based on the relationship between the known genetic
correlations of relative pairs and their phenotypic similarity.

Comparison of methods for association on Kosrae using simulated data

Data simulation:

The performance of candidate association methods was evaluated by analyzing simulated
datasets constructed from real BMI phenotype data in which no genome-wide significant
associations were found (Lowe 2009). For simulation, 1,000 SNPs were randomly
selected from Kosraen 500k Affymetrix genotypes and 770 remained after filtering
MAF>0.01. Using these SNPs, we generated a total of 770 genome-scale (~350K SNP's
each) simulated datasets, in which each phenotype (BMI) was “spiked” to represent a
dependency with one of 770 SNPs that contains an effect explaining an additional 2% of
phenotypic variance. Each simulated dataset, comprising 2,906 Kosraen individuals, was
deconstructed into a pedigree of 586 sibships of size ≥ 2 plus 240 individuals who were
less than first cousins (a total of 2,007 individuals) that could be handled by all four
methods. The four methods (FBAT, FBAT/Wald, Plink/QFAM-total and EMMAX) were
used to perform association for each of the 770 sibship-structured, simulated datasets.
Finally, in order to assess the full power of the EMMAX and FBAT/Wald methods, the
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simulated datasets were also re-analyzed by these methods, this time including an extra
310 individuals who did not fit into the sibship pedigrees (n= 2,317).

Association methods:

We performed comparative analysis for three different association approaches: a withinfamily test vs. a within- and quasi-between- family test vs. a within- and between- family
test. FBAT (version 2.0.2c) (Lange 2007) was chosen to represent a within-family test,
QFAM-total procedure in PLINK software (plink version 1.05) (Purcell 2007)
represented a within and partial between family model that utilizes a special permutation
procedure to account for family structure. And we selected EMMAX (pre-release beta
version) for representing a within- and between-family test, which handles all the
relatedness of the cohort (Kang 2010). As both FBAT and QFAM/PLINK do not support
association mapping in complex pedigree structures, the pedigree was broken down into
sibships (siblings without parents) as described previously (Lowe 2009) and these
sibships were used for testing each association method. We tested each representative
tool under additive models and with moderate parameters to optimize its behavior of
association mapping. For FBAT, we set minsize to 3, which is the required parameter of
minimum size of family to include for analysis, without loss of any data and biallelic test
under an additive model was performed with the default settings. QFAM was run under
the PLINK framework with the parameter of qfam-total, and the aperm parameter was
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also included for adaptive permutation. EMMAX analysis was performed by constructing
an IBS-kinship matrix and running association on default settings.

Association performance:

We evaluated the performance of each method by two metrics. First, a rank-based score
measured the p-value rank of the ground truth SNP in its own dataset. We compared the
aggregate of rank of ground truth SNP for the three different association methods and
considered the one that assigns more high ranks to ground truth SNPs to be the more
powerful method. The second metric was a p-value-based score, which measures the pvalue of the ground truth SNP in its respective dataset. With the sum of ground truth
SNPs exceeding a particular p-value threshold, we alternatively compared the power of
each method.

Association mapping of Kosraen traits using EMMAX

EMMAX was selected for association study of 31 Kosraen traits where low frequency
genotypes (MAF>0.01) were removed. A kinship matrix which captured the relatedness
between all pairs of phenotyped individuals for each trait was incorporated into the
EMMAX mixed model to test for association. Minimal score inflation was seen in the
nominal p-values for all traits.
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Since there is a high degree of linkage disequilibrium in our data, we determined a
genome-wide significance threshold by first extrapolating an approximate testing burden
from the trait data. The median minima p-value from 14 null traits was 1.6x10-6,
indicating an estimated testing burden of ~310,000 (actual number of tests was
~386,000). The genome-wide significance threshold for to account for multiple testing
for each trait was determined by Bonferroni correction based on the estimated testing
burden, i.e. 0.05/310,000 = p≤ 1.6x10-7. A study-wide significance threshold that also
accounts for testing multiple traits in the same study was determined conservatively using
the Bonferroni correction: 1.6x10-7/31 = p≤ 5.16x10-9.

For very strongly associated signal peaks ≤ 10-20 (such as those for URT, PPS, LPA), we
derive a more conservative empirical genome-wide significance threshold. The empirical
genome-wide significance threshold was calculated by the following steps: (i) phenotypes
were randomly permuted between individuals 1,000 times, accounting for family
structure, in order to generate 1,000 permuted genotype/phenotype datasets (ii) genomewide association analysis was performed for each permuted dataset, and the minimum pvalue recorded, (iii) the first percentile of the 1,000 genome-wide permuted minima was
set as the empirical genome-wide significance threshold (1.4 x 10-10). We considered a
nominal p-value observed in the real data to be genome-wide significant if it exceeded
the empirical genome-wide significance threshold.
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Identity-by-descent haplotype mapping in Kosrae

Identifying local haplotypes:

Genotypes for the entire Kosraean population were phased using the BEAGLE-trio
algorithm in one run according to the recommended parameters: 1 sample, 10 iterations
(Browning 2008). An 11 Mb region underlying the genome scan signal peak (chr2:3647MB) was excised for each individual and analyzed for pairwise IBD matching by the
GERMLINE algorithm (Gusev 2008). GERMLINE first identifies short “seed” regions of
30 SNPs that are identical across subsets of the population. Pairs of matching individuals
at a seed are then extended across flanking regions that are nearly-identical. We
registered haplotypes whenever pairwise comparison revealed a window of allele-call
identity at least 500 kb in length with up to 1% mismatch allowed for genotyping error

Haplotype clustering criteria:

Moving from the pairwise IBD segments generated by GERMLINE to a comprehensive
set of unique haplotypes required a novel clustering approach. We clustered in two ways:
first we identified sets of individuals that may have any amount of common sharing
within a region of interest; then we mapped the specific sharing boundary positions
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among individuals of interest. The first clustering methodology borrowed a graph-theory
approach for finding connected components. We constructed a graph where each
individual is represented as a vertex and a shared IBD segment across two individuals in
the region of interest forms a simple undirected edge between their respective vertices. A
connected component is a sub-graph in which any two nodes are connected by a path; in
our IBD graph, a maximally connected component represented all individuals that shared
a common haplotype. We used this approach to seek out sets of individuals sharing
common haplotypes whose mean phenotype deviated significantly from the expected,
designated “affected individuals”. We devised a second clustering methodology to
identified the specific physical boundaries of the unique region that is shared among
multiple individuals from the pairwise sharing data. Conceptually, this algorithm
iteratively layered pairwise shared segments between common individuals while keeping
track of the physical positions where each individual initiates or ends sharing with the
haplotype. Upon analyzing all pairwise shared segments, the algorithm generated, for
each marker along the region of interest, the sets of individuals that share a common
haplotype at that marker. These results were used to identify any region which was
shared exclusively by affected individuals.

PPS signal peak fine-mapping

An 11 Mb region underlying the genome scan signal peak (chr2:36-47MB) was excised
for each individual and analyzed for pairwise IBD matching by the GERMLINE
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algorithm (Gusev 2008). All 13 exons of the ABCG5 and ABCG8 genes including their
splicing donor/acceptor flanking sequences were PCR amplified and sequenced using the
Applied Biosystems 3730xl sequencer. Sequencing chromatographs were analyzed by
using the FinchTV 1.4.0 and DNASTAR Lasergene 8 software.

URT signal peak fine-mapping

93,629 distinct haplotype clusters were identified after filtering for haplotype clusters of
≥0.01 frequency ≥500kb in length. The haplotype clusters were associated to uric acid
levels using EMMAX (see above) and a 13 genome-wide significant haplotypes
spannning chr11:36.2-94.2MB emerged (p<8.52x10-8), with a chr11: 63.4-65.2 subregion being most significantly associated (p<9.06x10-46) .

Ashkenazi Jewish study population collection

Genome-scale genotype data was collected for 3,573 individuals of self reported
Ashkenazi Jewish (AJ) descent from seven different centers in New York, NY and Tel
Aviv, Israel. The data consisted of called genotypes assayed on either the Illumina 300k,
550K or IM or Affymetrix 500k or 6.0 platforms. The combined sample contains 966,
449, 554, 101 and 297 individuals who have been diagnosed with Crohn‟s disease,
Parkinson‟s disease, Schizophrenia, Dystonia and Non-Insulin dependent Diabetes,
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respectively. The sample also contains 1,680 “control” individuals for each of these
diseases.

Constructing a combined AJ dataset for genome mapping

Combining all AJ datasets:

All datasets were converted to PLINK format and low quality genotypes (missingness
>0.02) or individuals with missing genotypes (missingness >0.02) were excluded (-missing flag). Also excluded were genotypes with minor allele frequency <0.01 (--geno
flag). Ambiguous SNP‟s (those that are A/T or C/G) were removed from individuals
assayed on Affymetrix platform. If gender information was missing, it was inferred using
PLINK (--impute-sex flag) where the X chromosome SNPs were provided. Duplicate
samples within and between datasets were detected (n=9) using PLINK (--genome flag)
and one of the pairs was removed. Homozygous heterozygote SNP‟s were detected and
set to missing. Finally the eight datasets were merged in PLINK (--merge flag) to yield a
combined dataset of partial genotyping across the Affymetrix and Illumina platforms for
3,564 individuals. AJ ancestry for all samples was assessed by principal components
analysis across ~23K unlinked SNPs in the sample, including Jewish Hapmap AJ
samples (n=34), Hapmap CEU samples (n=164), and other non-AJ Jewish or middle
eastern samples from the Jewish HapMap and Human Genome Diversity panel (Ostrer
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2010). ~600 individuals were determined to have significant non-AJ ancestry and were
excluded from the analysis.

Constructing an AJ reference panel for imputation:

We constructed an AJ reference panel for 100 AJ individuals who had been typed on both
the Affymetrix 6.0 and Illumina 1M platforms, resulting in 1,778,360 genotyped SNP‟s
for these individuals. Genotypes with >0.02 missingnes, homozygous heterozyotes and
low frequency SNPs (MAF <0.02) were excluded. Ambiguous SNP‟s (A/T or C/G) on
the Affymetrix platform were also excluded. We attempted to recover these by BEAGLE
(Browning 2008) imputation, accepting on high quality imputed genotypes (r2>0.9).
Finally, 2 individuals who were discordant >0.008 were also excluded from the reference
panel. The final panel consisted of 1,328,536 genotypes in 98 individuals.

Imputing missing genotypes in the combined AJ dataset using the reference panel

Missing genotypes in the combined AJ dataset were imputed from the constructed AJ
reference panel using BEAGLE. Genotypes that were either poorly imputed (r2<0.9) or
had low frequency (MAF <0.01) were excluded from the subsequent analysis. The final
dataset contained 1,068,161 SNP‟s in 2,860 individuals.
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Mapping of AJ traits using EMMAX

Association for Crohn‟s disease (CD) was performed using EMMAX as described above.
In each case, the case‟s for CD (n=781) were compared to a combination of non-disease
controls and disease non-case controls (n=2,079 and n=2,411, respectively). To control
for strong genetic effects, the LRRK2 region was excluded from the CD analysis. To
account for batch effects between different platforms and/or datasets the association
between every pair of datasets (partitioned by case and control) were analyzed and
significant SNP‟s (<10-4) were excluded (n=7,227).

Computation

All analysis of the simulated datasets and real data were performed on a 3.0 GHz Intel
Xeon dual core 64-bit cluster containing 100 nodes (with 4 processors each), where each
node had 8-16GB of RAM.
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Chapter 3 Systematic haplotype analysis resolves a complex PPS locus

Introduction

Rapid technological advances in genomics over the last few years have focused on
identifying common genetic variants affecting complex disease risk. To date genomewide association studies (GWAS) have reproducibly implicated over 700 genomic
regions that modify the risk for over 120 complex diseases and health-related phenotypes
(Kruglyak, 2008, Manolio, 2008) . However, identifying the culprit causal variant(s)
underlying these local peaks in association signals remains a challenging task with only a
handful of causal variants identified so far (Burnett, 2008, Moffatt, 2007, Burkhardt,
2008). One conventional approach is sequencing a region of arbitrary length around the
signal peak across enough individuals to capture the causal allele. However, the larger the
sequenced interval and number of individuals, the more variants will be discovered
making it difficult to distinguish the driver allele from the large number of passenger
variants. This problem is exacerbated in cases where multiple, seemingly independent
signals reside in close proximity along the genome. Recent examples of multiple alleles
include the 8q24 region for prostate cancer(Haiman, 2007, Yeager, 2007, Gudmundsson,
2007), 6p21 region for HIV-1 viral setpoint (Fellay, 2007), the IL23R, 6p25 and 17q21
regions for Crohn‟s disease (Duerr, 2006, Barrett, 2008), the PNPLA3 region and
nonalcoholic fatty liver disease (Romeo, 2008) the IRF5, STAT4 and TNFAIP3 regions
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for systemic lupus erythematosis (Graham, 2007, Graham, 2008, Abelson, 2009) and the
6q23 region for rheumatoid arthritis (Plenge, 2007).

We introduce a method for exposing a causal variant in a region of a genome scan signal
that begins with the identification of the full set of haplotypes underlying the signal peak.
We assume that a causal derived allele enters a population as a mutation on the
background of an ancestral chromosome or haplotype and, under an infinite sites model,
that the allele is likely to have mutated only once on that unique ancestral haplotype
(Gabriel, 2002, Watterson, 1975). Haplotypes are subject to decay over time by
recombination events that occur with each generational meiosis, however mutations that
have occurred relatively recently may still be observable as common haplotypes. If
individuals in a population harbor a causal derived allele inherited from a recent
progenitor, they likely also share a very long segment of the ancestral DNA around the
allele. We previously developed the Genetic Error-tolerant Regional Matching with
LINear-time Extension (GERMLINE) algorithm (Gusev 2008) which performs pairwise
identity-by-descent matching to identify long shared genomic segments in a population.
Here, we combine GERMLINE with a novel clustering algorithm which groups similar
shared haplotypes to identify any common co-inherited haplotype that might associate to
a signal peak. By selecting long co-inherited haplotypes our approach avoids the
confounding effects of long range linkage disequilibrium faced by methods based on
shorter haplotypes (de Bakker, 2005, Durrant, 2004, Horvath, 2004, Schaid, 2002,
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Verzilli, 2006) and a reduced multiple test burden relative to other similar methods (Lin,
2004, Tregouet, 2009, Laramie, 2007, Purcell, 2007, Albrechtsen, 2009).
We tested our method in an extreme isolate founder population where we had previously
shown abundant long haplotype segments shared between individuals (Gusev, 2008,
Bonnen, 2006). The Pacific Island of Kosrae, in the Federated States of Micronesia, was
likely settled 2,500-1,500 years ago by individuals of Asian ancestry and Islanders have a
high incidence of obesity and diabetes (Gray, 2009, Friedlaender, 2008, Kayser, 2008,
Shmulewitz, 2006, Lowe, 2009). We focused on plasma plant sterol (PPS) levels, which
were ascertained as part of a broader study to examine genetic causes of the metabolic
syndrome on the island (Lowe, 2009).

Plant sterols are a dietary source of neutral sterols that are structurally similar to
cholesterol (Ostlund, 2002, Heinemann, 1993). Studies of the rare disorder
phytosterolemia, which is characterized by extremely high PPS and severe premature
atherosclerosis, have implicated mutations in the ATP binding cassette subfamily G
members 5 or 8 (ABCG5 or ABCG8) genes (Berge, 2000, Hubacek, 2001). The
ABCG5/ABCG8 genes form an obligate heterodimer that has been shown to be involved
in intestinal absorption and biliary excretion of neutral sterols, including plant sterols and
cholesterol (Graf, 2003). As such, PPS are considered to be a biomarker for dietary
cholesterol absorption and changes in the balance of cholesterol absorption and secretion
have been suggested to be atherogenic (Rudkowska, 2008, Sudhop, 2002). Further, it is
unclear whether moderately elevated PPS may themselves affect cardiovascular risk
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(Silbernagel, 2009, Fassbender, 2008, Chan, 2006). We had previously reported that
13.8% of Kosraens are carriers of an ABCG8 exon 2 frameshift mutation leading to a
nonsense ABCG8 codon (nonsense ABCG8 mutation) which results in a premature
truncation and non-functional protein. The ABCG8 nonsense mutation was shown to
effect a 30%-50% increase in plasma levels of campesterol and sitosterol, the two most
abundant plant sterols in plasma (Sehayek, 2004).
Here, we validated the ABCG8 exon 2 nonsense mutation effect in a larger Kosraean
cohort of ~3,000 individuals and performed an association analysis of PPS levels, which
implicated a second strong signal at the same locus. We analyzed identity-by-descent
(IBD) shared genetic segments using the GERMLINE software to dissect the full set of
long-range haplotypes in this region and identified a distinctive 526 kb haplotype,
independent of the ABCG8 nonsense mutation, which is carried by 1.8% of Kosraens and
associated with a striking 100% increase in PPS levels. Sequencing of the
ABCG5/ABCG8 genes in carriers of the 526 kb haplotype revealed a novel ABCG5
D450H missense mutation, a plausible putative causal variant in this haplotype. These
findings exemplify the power of haplotype analysis in resolving the effect of multiple
variants of the same locus.
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Results

Analysis of multiple signals on Chr2p21 for PPS

We performed a GWAS in 1,423 related individuals (who were phenotyped for PPS
levels) on the Pacific Island of Kosrae with genotypes from the Affymetrix 500k array
and incorporating the ABCG8 nonsense mutation we had separately genotyped. The
analysis revealed 48 SNPs, all on chromosome 2p21, that surpassed an empirical
permutation-based threshold (see methods for details) of genome-wide significance at a
nominal p-value of 110-10 (Figure 3.1(A)). The strongest signal confirmed the
association of the ABCG8 nonsense mutation (p<510-39) to PPS levels and validated our
previous finding in a subset of this cohort (Sehayek, 2004). Closer examination of the
signal at chromosome 2p21 revealed a broad signal peak with genome-wide significant
signals for PPS extending up to 10 Mb upstream and 1 Mb downstream of the
ABCG5/ABCG8 locus (Figure 3.1(B)). To determine whether this extended signal was
entirely accounted for by the ABCG8 nonsense mutation, we reanalyzed the association
of the PPS phenotype conditioned on the ABCG8 nonsense mutation genotype (Figure
3.1(C)).
Multiple strong signals that exceeded the genome-wide significance threshold up- and
downstream of the ABCG8 locus persisted and suggested the presence of additional
independent signals at this locus. The strongest remaining signal was associated with
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Figure 3.1 Stepwise conditional analysis of a genome-wide plasma plant sterol (PPS) levels: (A)
Unconditioned genome-wide association of PPS. Association analysis was performed as described in the
methods section. The red line marks the threshold of empirical genome-wide significance. (B)
Unconditioned association of PPS in a 11Mb interval on chromosome 2 surrounding the genome-wide peak
signal and the ABCG5/ABCG8 genes. Maroon square indicates the ABCG8 nonsense mutation with the
best signal. Red shaded area marks the ABCG8 locus. (C) Association of PPS in the same chromosome 2
interval after conditioning for the ABCG8 nonsense mutation. Blue square indicates the SNP (rs12185607)
with the best signal. (D) Association of PPS in the same chromosome 2 interval after conditioning for both
the ABCG8 nonsense mutation and rs12185607 genotypes.
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ABCG8 nonsense mutation

rs12185607
GG

GT

GG

2512

64

GC

321

2

CC

5

0

Table 3.1 Linkage equilibrium between the ABCG8
nonsense mutation and rs12185607/G allele

rs12185607 (p<3×10-31) ~250 kb downstream of the ABCG5/ABCG8 locus. To examine
the possibility of additional independent signals, we analyzed the association of PPS
phenotype conditioned on both the ABCG8 nonsense mutation and rs12185607.
Conditioning of PPS on both variants abolished statistically significant signals across the
genome, as shown in Figure 3.1(D), and specifically at the chromosome 2p21 interval.
We observed that the effects of the ABCG8 nonsense mutation and rs12185607/G were
in the same direction and the minor alleles were the risk alleles in both cases. Given the
carrier rates of 11.1% and 1.8% of the ABCG8 nonsense mutation and the
rs121185607/G minor allele, respectively, we expected to find 5-6 Islanders carrying
both alleles. We observed only two individuals (p=0.076 assuming independence) who
were carriers of both minor alleles. Therefore, our findings suggested the presence of two
independent variants effecting PPS at the chromosome 2p21 locus.
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Systematic identification of a novel PPS
haplotype at chr2p21

To capture the second causal allele on
chromosome 2p21 we devised an analysis
pipeline to systematically identify all common
haplotypes in the region (see Figure 3.2). The
11 Mb signal region on chromosome 2p21
(chr2:36-47MB) around the ABCG5/ABCG8
locus was excised and common haplotypes
were identified by IBD matching using
GERMLINE

(Gusev,

2009).

The

IBD

segments were at least 500 kb in length and
Figure 3.2 Schema of the analysis pipeline
for novel PPS haplotype discovery,
refinement and validation. BEAGLE-trio
phased haplotypes for the chromosome 2
region (36-47MB) were excised and analyzed
with GERMLINE to detect matching
pairwise IBD segments. Overlapping
segments that matched across the population
were clustered and these the mean phenotype
of cluster members was assessed. One cluster
containing a 1.3MB haplotype strongly
associated to high PPS levels. Careful
comparison of haplotypes in that cluster
revealed a unique ~526kb shared segment
carried by 52 individuals. The CRANEFOOT
software was used to visualize the ~526kb
haplotype segregating in three closely related
kindreds.

allowed for up to 1% mismatching due to
genotyping error. Next, we clustered groups
of

similar

haplotypes

using

similarity

measures and binned together sets of
individuals that had common sharing within
the 2p21 region. These efforts identified
3,681,003 pairs of individuals that shared
one or more IBD matching segments >500
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kb in length. These matched pairs clustered to 233 bins of common sharing with >99%
sequence identity (see Figure 3.3). We found a single cluster containing 44 individuals
that shared a 1.3 Mb haplotype strongly associated with PPS levels (p<4x10-65). This
haplotype was shared by eight additional individuals who were not phenotyped for PPS
levels. We mapped the specific sharing boundaries of the haplotype to a 526 kb subregion (chr2:43.8-44.3 Mb) that was unique to this group of 52 individuals (see Figure
3.4(A)). Fourteen individuals (six phenotyped), who were carriers of rs12185607/G but
were not on the background of the 526 kb haplotype, had significantly lower PPS levels
(p=5.2 x 10-4).

Figure 3.3 Histogram of haplotype cluster sizes. The x-axis shows the
haplotypes binned by the number of haplotypes in each cluster and the number
of clusters for each bin is shown on the y-axis.
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Figure 3.4(A) Annotated genes on the background of the 526 kb haplotype. The novel PPS haplotype
(indicated as a grey bar) extends over a 526kb region on chromosome 2p21 that includes the ABCG8 and
ABCG5 candidate genes (indicated by a black dashed square) and also fully or partially 5 other annotated
loci (Ensembl Homo sapiens version 54.36p (NCBI 36) Chromosome 2 : 43,000,000 .. 45,000,000
[54]).(B) Effect of the ABCG8 nonsense mutation and 526 kb haplotype carrier state on PPS. Fasting
plasma levels of campesterol and sitosterol were determined as described in the Methods section. Values
shown are Mean  SEM.

Clustering of the novel PPS haplotype in three Kosraean pedigrees

We investigated the family structure of the 52 carriers of the 526 kb haplotype. This
haplotype segregated in three kindreds containing 110 genotyped individuals from the
same village, and was present in one unrelated individual (see Figure 3.5). There were
two carriers of both the 526 kb haplotype and the ABCG8 nonsense mutation, each
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inherited from a different parent. We performed admixture analysis, using the
ANCESTRYMAP algorithm (Patterson, 2004) trained on four Hapmap phase III
reference panels (CEU, CHB, JPT, GIH) to examine the ancestral origin of the 526 kb
haplotype, and found no evidence of admixture in the region.

The three kindreds segregating the PPS haplotype came from the same village, opening
the possibility that a shared local environment or other non-genetic factor might cause
increased PPS levels in the whole village and, hence, false positive association signals
among this sub-population. To control for any confounding local environment in the
village, we coded PPS haplotype carrier status as an allele (1=carrier, 0=non-carrier) and
performed association analysis with PPS levels. 89 phenotyped villagers who fell into 39
nuclear families were analyzed with PLINK/QFAM and the PPS haplotype remained
significantly associated with PPS levels in this sub-group with a permuted p-value<1.6 x
10-4.
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Figure 3.5 Segregation of PPS haplotype in three kindreds from one village. The pedigree structure of 146 individual forming three kindreds and one
unrelated individual from the same village on Kosrae. PPS haplotype carriers are shown in horizontal strips. Non-carriers are shown in white. 36 non-genotyped
individuals (shown in solid grey) are include to preserve the kindred structure.
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Phenotypic effect of the 526 kb haplotype
Previous analysis in a subset of the Kosraen cohort revealed that carriers of the ABCG8
nonsense mutation are characterized by a 30-50% increase in plasma campesterol and
sitosterol levels, but no alteration in plasma cholesterol levels (Sehayek, 2004). Here, we
have examined the effect of the ABCG8 nonsense mutation and the 526 kb haplotype on
PPS and plasma lipid levels in the entire cohort. As shown in Figure 3.4(B), carriers of
the ABCG8 nonsense mutation had a 50-54% increase in mean plasma campesterol (2.00
± 0.87 vs. 1.33 ± 0.52) and sitosterol (1.85 ± 0.81 vs. 1.20 ± 0.48) levels compared to
non-carriers (in both cases p<0.0001). Also shown in Figure 3.3(B), carriers of the 526
kb haplotype had a 109-117% increase in mean plasma campesterol (2.78 ± 1.01 vs. 1.33
± 0.52) and sitosterol (2.61 ± 1.00 vs. 1.20 ± 0.48) levels compared to non-carriers (in
both cases p<0.0001).
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Total
Population

0.66

Non-carriers

ABCG8
mutation
carriers

1.52 ± 0.67
(1687)

1.33
(213)

±

0.55

170.2
(315)

±

34.48

PPS haplotype
carriers

Non-carriers
vs
ABCG8 mutation
carriers

Non-carriers vs
PPS haplotype
carriers

0.84
(44)

1.08 x 10-4

3.68 x 10-11

<0.0001

167.55 ± 34.92
(52)

0.022

N.S.

N.S

Lath:Chol

1.50 ±
(1900)

TC
(mg/dL)

166.09 ± 34.43
(2819)

165.48
34.35
(2452)

LDL-c
(mg/dL)

102.1 ±
(1899)

29.54

101.63 ± 29.3
(1645)

105.42 ± 30.63
(210)

100.84 ± 30.73
(44)

N.S.

N.S.

N.S

ApoB
(mg/dL)

86.97 ±
(1884)

21.32

86.65 ± 21.31
(1621)

88.53
(219)

±

21.64

89.7
(35)

±

19.8

N.S.

N.S.

N.S

HDL-c
(mg/dL)

38.28 ±
(1899)

11.04

38.09 ± 10.95
(1645)

38.77
(210)

±

11.36

42.00
(44)

±

9.93

N.S.

N.S.

N.S

ApoA1
(mg/dL)

116.87 ± 24.39
(1875)

116.64
24.07
(1621)

118.07
(219)

122.21 ±
(35)

25.3

N.S.

N.S.

N.S

±

±

±

26.5

±

0.38

Non-carriers
vs
ABCG8 carriers vs
PPS carriers

100.94
±
95.58 ± 39.02 93.26 ± 36.32
45.91
0.05
N.S.
N.S
(315)
(52)
(2450)
Table 3.2 Lathosterol:cholesterol and other plasma lipid levels. ANOVA analysis of lathosterol:cholesterol and plasma lipid levels comparing carriers of the
ABCG8 mutation and 526 kb haplotype and individuals who are wildtype for both mutations. Values are shown as the mean ± standard deviation, with the
number of individuals shown in brackets. N.S.: not significant, Lath:Chol: lathosterol/cholesterol ratio, TC: total cholesterol, LDL-c: low density lipoprotein cholesterol,
TG
(mg/dL)

99.94 ±
(2817)

46.16

HDL-c: high density lipoprotein cholesterol, TG: triglycerides, ApoA1: Apolipoprotein-A1, ApoB: Apolipoprotein B.
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The effects of the ABCG8 nonsense mutation and the 526 kb haplotype on plasma lipid
levels were next examined. As shown in Table 3.1, the only significant finding was a
modest increase in total cholesterol levels in the ABCG8 nonsense mutation carriers. The
effect of these two variants in the ABCG5/ABCG8 region on plasma lathosterol levels
was also assessed. Plasma lathosterol levels have been shown to be proportional to
whole body cholesterol synthesis. Also shown in Table 3.1, carriers of the ABCG8
nonsense mutation had a 12.5% decrease in plasma lathosterol (standardized to
cholesterol and shown as a ratio of lathosterol:cholesterol) (1.33 ± 0.55) and carriers of
the 526 kb haplotype a 45% decrease in plasma lathosterol (0.84 ± 0.38) compared to
non-carriers (1.52 ± 0.67) (in both cases p<0.0001).

Sequencing reveals a novel putative ABCG5 causal variant

The 526 kb haplotype region on chromosome 2p21 encompasses both ABCG5 and
ABCG8 and six other annotated genes (see Figure 3.6). ABCG5 and ABCG8 are
obvious candidate genes to explain the haplotype effect. We first sequenced all 13 exons
and adjacent intronic splice donor/acceptor site flanking sequences of these genes in four
pairs of 526 kb haplotype carriers and non-carrier related controls. As shown in Figure
3.6, this effort revealed a novel ABCG5 exon 10 missense mutation resulting in a coding
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change from negatively charged aspartic acid to positively charged histidine at residue
450 (D450H). This aspartic acid is highly conserved in vertebrates, suggesting a
functional role that might be subverted by the histidine substitution (see Figure 3.6).
Finally, to confirm association of the 526 kb haplotype to the ABCG5 missense mutation
we sequenced exon 10 of ABCG5 in the remaining 48 carriers, 10 non-carrier controls,

Figure 3.6 D450H missense mutation in exon 10 of the ABCG5 gene. The sequencing chromatograph
showing the G to C mutation that results in a coding change from aspartic acid (D) to histidine (H) at codon
450 in exon 10 of the ABCG5 gene. The aspartic acid is highly conserved in vertebrates.

and 13 carriers of rs12185607/G but not the 526 kb haplotype. The ABCG5 missense
mutation was only present in the 526 kb haplotype carriers; thus establishing complete
linkage disequilibrium between the 526 kb haplotype and the ABCG5 missense mutation.
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Discussion

We present the first implementation of a novel approach for leveraging common coinherited haplotypes under the local peak of a genome scan to expedite the search for the
culprit causal variant. We analyzed a strong genetic trait, plasma plant sterol levels, in an
extreme isolate population known to segregate a defined ABCG8 nonsense mutation on
chromosome 2p21. Our initial GWAS analysis revealed evidence for multiple
independent signals in the chr2p21 region. Systematic dissection of common haplotypes
in that region using the GERMLINE software identified a single common haplotype that
harbored a second PPS signal. Re-sequencing the exons of two candidate genes in the
haplotype, ABCG5 and ABCG8, revealed a plausible causal genetic variant.

The advantage of the IBD approach is that long shared segments bearing causal variants
are unlikely to be shared by chance, thereby increasing their power for detection over
traditional association mapping. Furthermore, this approach exactly identifies carriers and
can be used to dissect multiple signals at the same locus. In the current study it was
possible to detect a relatively rare (minor allele frequency < 1%) causal genetic variant.
Since IBD haplotypes were constructed from SNP-chip data, this approach can
complement a traditional association mapping method. However, the method is only
suited to discover rare, relatively newly arisen or bottlenecked causal mutations that
retain enough surrounding shared DNA to be detectable. If a causal mutation arose more
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distantly and surrounding haplotypes are too short the method will not have any mapping
power. For example, the ABCG8 nonsense mutation was entirely described by a short
~4kb haplotype and was not detectable by this method. The IBD approach to search for a
causal allele affecting PPS was aided by the high degree of relatedness and founder
effects on Kosrae that resulted in abundant, long haplotypes in our study population.
However, recently tracks of relatedness in regions of the genome have been seen in less
extreme founder populations (Kong, 2008), and even in apparently unrelated populations
(Frazer, 2007). This has motivated several groups to develop IBD methods as a means of
mapping disease-related alleles (Gusev, 2009, Purcell, 2007, Albrechtsen, 2009).

The unexpectedly large phenotypic effect of the 526 kb haplotype on PPS levels raises
intriguing questions regarding the underlying mechanism. Given the evolutionary
conservation of the aspartic acid residue in position 450 of ABCG5 and the
nonconservative nature of the amino acid substitution, this variation is highly likely to be
functional. It is unclear, however, how a missense mutation in ABCG5 elevates PPS
levels ~100%, whereas an ABCG8 nonsense mutation, presumably yielding no full
length protein, only elevates PPS levels ~50% (see Figure 3.3). It has been shown that
ABCG5 functions by heterodimerization with ABCG8 (Graf, 2003).

Therefore, we

hypothesize that the greater effect of the missense mutation is due to one of the
following: (i) imbalanced expression of a non-functional ABCG5-mutant allele, (ii) a
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gain-of-function dominant-negative ABCG5 mutation, or (iii) linkage disequilibrium of a
non-functional ABCG5-mutant with other genetic variant(s) at the 526 kb haplotype.

Recent well-powered meta-analyses of pooled GWAS in individuals largely of Caucasian
ancestry found the ABCG5/ABCG8 locus associated with plasma total and LDLcholesterol levels (Kathiresan, 2009, Aulchenko, 2009). In the current study we found a
modest association of the ABCG8 nonsense mutation with total cholesterol levels
(p<0.02), but no such association for the 526 kb haplotype containing the ABCG5
missense mutation. This is a paradox as the greater potency of the latter mutation is
verified both by a larger increase in PPS levels and a greater decrease in cholesterol
synthesis as shown by more of a decrease in plasma lathosterol levels. It is possible that
the frequency of the 526 kb haplotype is too low for an effect on plasma cholesterol to be
seen. It is also possible, but unlikely, that the 526 kb haplotype contains other variants
besides the ABCG5 missense mutation that obscure effects on total and LDL cholesterol,
while preserving affects on PPS and plasma lathosterol levels. Finally, the number of
ABCG8 nonsense mutation carriers are relatively few in this study, especially compared
to population based studies, and the borderline association seen with total cholesterol
levels may be a false positive.

Mutations in ABCG5 and ABCG8 are rare in the general population. Homozygotes or
compound heterozygotes have the disorder phytosterolemia at an estimated frequency of
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<1:1,000,000 (there are only 40 reported cases).

It is therefore interesting that we

observed by sampling ~3,000 adults on Kosrae a combined carrier rate of 1:8 for the two
mutations.

The reason for such clustering is not clear, but may suggest a beneficial

effect of these mutations or simply a chance observation owing to founder effects.

In summary, we have described a novel approach to identify and dissect the effects of
large haplotypes under the signal of a single locus detected by GWAS. This approach
allowed identification of a novel 526 kb haplotype that modifies PPS and dissected its
effect from an ABCG8 mutant that was known to segregate on the island of Kosrae.
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Chapter 4 Comparison of Association Methods in Isolated Populations

Introduction

Isolated populations have a long history in genetic mapping studies of inherited disorders
with

advantages

including reduced environmental,

phenotypic and genotypic

heterogeneity as compared to outbred populations (Ober, 2001 ,Angius, 2002 ,Peltonen,
1999 ,Gulcher, 2001 ,Freimer, 1996 ,Zamel, 1996 ,Abney, 2000 ,Aulchenko, 2004 ,van
der Walt, 2005). In particular, the reduction of genotypic heterogeneity observed in
isolated populations due to founder effects, bottlenecks and genetic drift, may allow
otherwise rare mutant alleles to rise to higher frequency in these populations, while at the
same time narrowing the spectrum of candidate mutations (Ober 2001, Angius 2002).
The increased chance for homozygosity has been a key factor in identifying mutations
responsible for rare monogenic diseases in isolated populations (Peltonen 1999, Gulcher
2001, Freimer 1996). Here we investigate the advantages and limitations of exploiting
homozygosity in isolated populations for analysis of alleles effecting complex traits
(Zamel 1996, Abney 2000, Aulchenko 2004). Genome-wide association studies (GWAS)
performed in outbred populations have thus far identified many common variation
contributing to complex diseases (Manolio 2008). One limitation in these studies is that
rare variants that are not in linkage disequilibrium with the common variants assayed are
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usually not detected (Bodmer, 2008). However, when the populations analyzed in a
GWAS have a substantial number of individuals that share a recent common ancestor, not
only common variants (Lowe, 2009, Wang, 2009), but sometimes also rare variants
affecting complex disorders can be identified (Sabatti, 2009, Pollin, 2008, Kallio, 2009).

Genetic analysis of isolated populations pose unique challenges for traditional GWAS
methods that have been mainly focused on outbred populations (Bourgain, 2005). The
crux of the difference is that in isolated populations the likelihood of any two individuals
in the population to be related is not negligible. The resulting direct and cryptic
relatedness confounds assumptions of independence between genotypes of different
individuals, as well as between their heritable phenotypes. Isolated populations therefore
contain a large amount of cross-individual correlations which pose problems for most
mapping methods. Further, consanguinity may be present so that two alleles in a random
individual may also be correlated. The hidden correlation in the data can cause an
overdispersion of the naïve test scores for association and consequently, lead to false
positive associations. Hence, the major challenge for performing GWAS in isolated
populations is to account for this non-random intra- and inter-individual correlation.

While standard association tests assume independence of genotypes and phenotypes
across samples, several specialized approaches for association do account for underlying
relatedness expected in isolated populations. In this work, we set out to select and
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evaluate these different methods for maping complex traits in an isolated founder
population. Some of these methods rely on knowledge of the underlying family structure
in the population. These approaches overcome the confounding effects of non-random
correlation via deconstruction of the population into family units and analysis of
association independently within each unit (within family variance) (Lange, 2004
,Abecasis, 2000 ,Almasy, 1998). Some of these “family-based” methods have been
extended by adding the variance between families to the within family variance (Devlin,
1999, Purcell, 2007, Abecasis, 2001,Abecasis, 2002 ,Won, 2009). A different type of
“population-based” approach does not utilize prior knowledge of family structure, but
rather explicitly models the relatedness between all pairs of individuals based on their
genotypes, and incorporates this variance into a mixed model for association (Yu, 2006
,Abecasis, 2001 ,Kang, 2008, Aulchenko, 2007, Amin, 2007, Kang, 2010, Zhang, 2010).
Such models have recently been extended to genome-scale human studies and have been
shown to effectively control for population structure (Zhang, 2010, Kang, 2010). Here
our emphasis is on evaluation of such methods in the context of extensive relatedness in
study samples.
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Figure 4.1: Schema of the sibship- and kinship matrix- based approaches to association studies in related
cohorts. (A) The extended Kosrae pedigree is broken into sibships without parents (indicated by the dotted
gray circle). Parent-child or cousin relationships may exist between different sibships. Tests of association
may be performed within sibships (gray arrows) and between sibships (black arrows). (B) A kinship matrix
of all pairs of the same individual.
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We compared the performance of the four representative methods that account differently
for relatedness while testing for genome-wide association: (i) focusing on allele
transmission to offspring within families (Lange, 2004), (ii) measuring association within
as well as between families (Devlin, 1999 ,Purcell, 2007, Won, 2009), and (iii) capturing
the relatedness between all individuals in the population to construct a mixed model to
test for association (Kang, 2010). Our simulations showed the mixed model method to
have increased statistical power to detect association, offering a 1.8- to 2-fold
improvement over the family-based approaches.

Results

Computational performance

Five representative programs for performing association in the context of relatedness
(FBAT, FBAT+Wald, PLINK/QFAM-total, EMMAX and SOLAR – see description
below) were assessed for speed and maximum memory allocation to determine their
suitability for a genome-scale association analysis across thousands of individuals. The
average computation time for association per marker for each program is given in Table
4.1. FBAT, FBAT+Wald, EMMAX and PLINK/QFAM-total ran at speeds < 0.06
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FBAT

FBAT+Wald

PLINK/QFAM-total

EMMAX

SOLAR

0.013

0.021

0.057

0.039

8.74

1,660

1,660

760

790

3,200

Speed
(sec/SNP)
Memory
(MB ram)
Table 4.1: Computation time (average computation time per second per SNP) and maximum memory
allocation (megabytes of RAM) for each association methods (FBAT, PLINK/QFAM-total, EMMAX and
SOLAR).

seconds/SNP, with FBAT performing > 2-fold faster than the other three methods,
compared to the SOLAR method which was > 100-fold slower. The slow speed of the
SOLAR method prohibited its further inclusion in the study. The maximum virtual
memory allocation required by the remaining four methods did not exceed 1.7GB of
RAM during the runtime of each program.

Strategy for accuracy and efficacy comparison on known-answer data

We evaluated the performance of different approaches to genome-wide association in the
context of relatedness by comparing representative tools for each approach. The familybased association test (FBAT) is a method that considers allele transmission to offspring
within families (Lange, 2004). The FBAT group has recently suggested an extension of
their method that combines the within-family FBAT score with a rank-based, betweenfamily score, derived from a Wald test of the whole cohort, that is robust to
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overdispersion, into one single test statistic (FBAT+Wald), which we also tested (Won,
2009). Plink family-based association test for quantitative traits, within- and betweenmode (PLINK/QFAM-total), uses a linear regression-based between/within family
approach similar to a model described previously (Abecasis, 2000, Fulker, 1999). In the
PLINK/QFAM-total framework, confounding effects of family structure are controlled
by independent within- and between-family permutation strategies for estimating exact
significance levels, where the empirical within-and between family permuted p-values
are combined to a single score. We corrected for any residual overinflation of the test
statistic by standard genomic control adjustment (Devlin, 1999, Purcell, 2007). Finally,
efficient mixed model association expedited (EMMAX) is a method that first uses highdensity genotypes to empirically estimate levels of relatedness between every pair of
individuals, which are captured in a kinship matrix. The kinship matrix is then
incorporated into a linear mixed model to adjust for correlation in the phenotypic
distribution during association mapping (Kang, 2010). We used all four methods to
perform genome-wide association analysis in a highly related, population-based cohort
from the Island of Kosrae, Micronesia, that is comparable in size (n = 2,906) to published
single study case/control cohorts.

In order to assess the empirical power for each association method, we considered data
for over 350,000 SNPs, with a minor allele frequency greater than 0.01, genotyped on an
Affymetrix 500K platform in the Kosrae samples. We repeatedly analyzed association of
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these SNPs to a null, moderately heritable (h2 = 0.42 on Kosrae) phenotype, body mass
index (BMI), which we modified afresh multiple times. Each modified phenotype
included a simulated genotype/phenotype association explaining 2% of the phenotypic
variance to a different random SNP, additively combined to the true trait value. This
effect size was chosen to echo milder effects detected and detectable in larger-sample
studies that are now available. These datasets were constructed by selecting 1,000 SNPs
randomly across the genome (770 common SNPs after filtering, see methods), where
each phenotype was altered to reflect association to a different SNP in the random subset.
In total, 770 genome-scale datasets containing modified SNP-phenotype association were
generated and analyzed by all four methods.

Following extensive pedigree construction based on genetic and oral information, more
than 90% of the genotyped individuals on Kosrae form a single extended pedigree
spanning 5+ generations and containing numerous consanguineous offspring and multiple
marriage loops (Lowe, 2009). To the best of our knowledge, large pedigrees with such
complexity cannot be handled whole by methods that have a within-family component.
Therefore, we broke our pedigree into smaller units of sibships-without-parents for the
purposes of method comparison. This resulted in 586 sibships consisting of two or more
individuals who share a mother and father (Figure 1A). Any genotyped parents are
considered only in the context of the parents‟ sibship. Of the individuals not included in
any sibship (n = 612), a subset was identified in which any two members of the subset
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were related to the degree of first cousins or less, as determined by genome-wide
identity-by-descent sharing, resulting in 240 additional “sibships” of size 1. To fairly
compare FBAT and PLINK/QFAM-total to EMMAX and FBAT+Wald, we first
analyzed only sibship individuals. However, to also quantify the benefits of using the
entire dataset, we repeated the analysis examining the entire cohort with EMMAX and
the sibships for the FBAT and entire cohort for the Wald components of the FBAT+Wald
method.

Empirical power results

The empirical power for each method was recorded in two ways: the reported (i) genomewide rank (Figure 4.2A) and (ii) p-value (Figure 4.2B) of the ground-truth SNP
according to each method across repeated simulation iterations. While these criteria are
equivalent when reported p-values are uniformly distributed (as required by the definition
of a p-value), inclusion of both criteria facilitates evaluation of potential bias in such
distributions. Comparison of the within-family only (FBAT) vs. combined within- and
between-family (PLINK/QFAM-total and FBAT+Wald) vs. mixed model (EMMAX)
tests demonstrated that the greatest power, as measured by rank order of the true effect,
was obtained by the use of the mixed model method. EMMAX had 88% power to rank
the true SNP in the top 10 genome-wide, a 1.7-, 2- and 2.1-fold improvement over
PLINK/QFAM-total, FBAT and FBAT+Wald, respectively (Figure 4.2A). In addition,
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56% of truly associated SNPs achieved genome-wide significance (gws) for the mixed
model method compared to < 16% for the other methods (Figure 4.2B – see discussion).
Although, the inclusion of the entire cohort (an additional ~300 individuals that did not
fall into sibships) in the FBAT+Wald method increased the number of truly associated
SNPs that achieved gws to 21%, this was less than half of the gws SNPs EMMAX
detected.

The improvement in power was also observed in comparison of the

PLINK/QFAM-total naïve test scores (i.e. not adjusted for genomic control) with
EMMAX, indicating that the dampening effect of the lambda correction does not account
for the total power difference between the two methods (Figure 4.2B). Finally, the
EMMAX analysis of the entire cohort showed a further 1.2-fold increase in power for the
top 10 ranked ground truth SNPs, with an additional 10% of SNPs surpassing genomewide significance compared to the EMMAX analysis of the sibships.
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Figure 4.2: Empirical estimation of power of association for four representative association methods for
related cohorts. (A) The aggregate rank of the ground truth SNP across 770 simulated dataset for
association performed with FBAT, FBAT+Wald, PLINK/QFAM-total + genomic control and EMMAX
with sibship structured (n = 2,007) and FBAT+Wald and EMMAX with all individuals (n = 2,317). (B) The
aggregate p-value‟s of the ground truth SNP for association performed with FBAT, FBAT+Wald,
Plink/QFAM-total + genomic control, Plink/QFAM-total without genomic control and EMMAX with
sibship structured and FBAT+Wald and EMMAX with all individuals.
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Discussion

To determine which association method would be best powered to analyze a highly
related isolate population, we compared four methods utilizing different approaches for
capturing underlying population structure. One of the methods measured variance within
family units and three of the methods added the variance between families using different
strategies to control for the over-inflation of the naïve score that resulted from the sample
structure. Two of the approaches uniformly rescaled the markers by adding a rank-based
p-value to a score or adjusting the score for overinflation by genomic control. These
approaches reduce false positives, but also lead to decreased power for true positives. The
mixed-model approach modified the test statistic in a marker specific way, which in turn
changed the ranks of associated results, so that false positives are reduced, but true
positives did not change. In our evaluation of four representative methods for mapping
disease alleles in highly related isolated populations, we found that the mixed-model
method significantly outperformed the other three methods. The power difference was
indeed in part due to the over-conservative uniform adjustments, but they did not account
for all the power difference between the two methods. The kinship matrix incorporated in
the mixed-model likely captured more between-family variance than the other methods.
Further, since the mixed-model method was not restricted to families, an analysis across
the whole sample increased the power.

72

Handling hidden and direct relatedness in the context of a mixed-model has both
theoretical and practical advantages over other approaches for association testing in
closely-knit, isolated cohorts. Theoretically, it handles relatives distant and close,
demographic trends and complex pedigrees (variation both within and between families
is utilized) and the test statistic produced is uniformly distributed, with no artificial
overdispersion of the p-value. Practically, the ability to include all samples in the analysis
gave a > 2-fold boost in power and our empirical results support the use of mixed-models
for association in populations such as our Kosrae samples.

It is worthwhile reviewing our work in the context of recent ideas and results in
association analysis. Specifically, the emerging picture is that despite comprehensive
scans of association with common SNPs of multiple complex phenotypes, only a limited
fraction of their heritable component has been identified (Frazer, 2009, Hindorff, 2009,
Frazer, 2009, Hindorff, 2009, Frazer, 2009, Hindorff, 2009). Expanding the search for
associated alleles to variants that are rare in the general population provides another piece
of this heritable component, with multiple gene sequencing studies implicating such
variants with moderate to high penetrance (Fearnhead, 2004, Cohen, 2004, Kotowski,
2006, Romeo, 2007, Marini, 2008, Fearnhead, 2004, Cohen, 2004, Kotowski, 2006
,Romeo, 2007, Marini, 2008, Fearnhead, 2004, Cohen, 2004, Kotowski, 2006, Romeo,
2007, Marini, 2008). Our experiences in association testing in an isolated population can
serve as a model for other studies of similar cohorts. Methodologically, mixed-models
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optimally extract association information from such samples. As GWAS cohorts increase
in size to the 6-digit range, and inclusion of somewhat related individuals becomes a
practical modus operandi, results in this work are expected to become relevant to a wide
range of populations.
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Chapter 5 Association mapping of 30 metabolic traits on Kosrae

Introduction

It has been shown that the limited genetic diversity and reduced allelic heterogeneity
observed in isolated founder populations facilitates discovery of loci contributing to both
rare monogenic traits and complex disease (Peltonen, 2000, Gulcher, 2001, Heutink,
2002). A strong founder effect, severe isolation and substantial inbreeding have
dramatically reduced genetic diversity in the indigenous population form the island of
Kosrae, Federated States of Micronesia(Lowe, 2009, Bonnen, 2006). The Islanders also
exhibit a high prevalence of diabetes, obesity and other metabolic disorders (Shmulewitz,
2001). Here we present a genome-wide association study of 30 traits pertaining to
metabolic disorder and electrocardiographic measures on the island.

Mapping in large, highly related, multi-generational cohorts is analytically challenging,
as extensive relatedness between subjects violates assumptions of independence upon
which traditional association tests are based. However, rigorous power analysis of several
specialized methods designed to accommodate complex familial relationships revealed
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that a mixed model approach optimally extracted association information from such
samples, demonstrating that population isolates have similar power to non-isolate
populations (see Chapter 4). Therefore, we used the mixed model method for genome
scans in 2,906 related individuals from the Island of Kosrae, Federated States of
Micronesia, who were previously genotyped for over 350,000 SNPs.

We re-analyzed data for 17 phenotypes previously studied in this cohort (Lowe, 2009,
Smith, 2009), along with 8 additional phenotypes. As positive controls, we observed nine
genome-wide significant associations with known loci of measured levels of plasma
cholesterol, high density lipoprotein, low density lipoprotein, triglycerides, thyroid
stimulating hormone, homocysteine, C-reactive protein and uric acid, with only one
detected in previous analysis of the same traits(Lowe, 2009). In addition, we refined the
broad signal peak for uric acid levels (chr11:59.1-65.3MB) by analysis of identity-bydescent (IBD) shared genetic segments and dissected the full set of long-range shared
haplotypes in this region. We identified a single 3% carrier frequency haplotype that
accounted for the entire signal in that region, and replicated one of the two previously
known signals, refining that signal by a factor of four. Finally, we show a region of novel
association for height (rs17629022, p<2.1x10-8).
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Results

Sample Ascertainment
We performed a population-based screen of native Kosraens over three separate visits to
the Island in 1994, 2001 and 2003 (Shmulewitz, 2006, Shmulewitz, 2001, Lowe, 2009) –
see Table 5.1. Self –reported family relationships were recorded for use in constructing
pedigrees and blood was collected for DNA extraction and genotyping. Genetic accuracy
of the Kosrae pedigree was assessed using pairwise identity-by-descent (IBD) estimates
generated in PLINK (Purcell, 2007) (see Materials and Methods).The total number of
unique individuals from the three screens that were successfully genotyped was 2,906,
representing >75% of the adult population on the Island.

N total

N unique

%Males/Females

Mean age

Median age

Age range

1994

1,935

903

49.6/50.4

43

39

20-86

2001

1,968

889

40.8/59.2

28

24

16-80

2003

84

33

51.5/48.5

24

22

16-53

-

1,081

35.3/64.7

47

46

17-89

3,987

2,906

41.6/58.4

40

38

16-89

Multiple
exams
Total

Table 5.1 Study participants successfully genotyped for the Affymetrix 500k assay. Screenings tood
place in 1994,2001 and 2003. For each screen, the total and unique number of individuals examined is
shown, as some participants were examined in multiple screens. For subjects examined more than once, age
(years) is reported form the most recent exam.
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Phenotypes pertaining to Metabolic Syndrome and Electrocardiographic measures

A rich, 30-strong phenotypic dataset

was

collected that included multiple

anthropomorphic and Metabolic Syndrome related phenotypes: height(HGT), weight
(WGT), waist circumference (WST), bodpod percentage fat assessment (PCF), body
mass index (BMI), leptin hormone levels (LEP), diastolic blood pressure (DBP), systolic
blood pressure (SBP), total cholesterol levels (TC), low-density liprotein cholesterol
levels (LDL), high-density lipoprotein cholesterol levels (HDL), triglyceride levels (TG),
campesterol levels (CMP), sitosterol levels (SIT), lathosterol levels (LAT) (CMP, SIT
and LAT are collectively called plasma plant sterols (PPS)), fasting plasma glucose
(FPG), haemoglobin A1C levels (HBA1C) and insulin sensitivity (INS). In addition, a
number of metabolic hormone and inflammation markers were collected: C-reactive
protein (CRP), thyroid stimulating hormone (TSH), homocysteine (HOMO), folic acid
(FLT), uric acid (URT) and creatinine levels, from which glomular filtration rates were
derived (GFR). Finally, a set of electrocardiographic measurements were taken on the
Island and a number of electrocardiographic conductance metrics were derived: QRS
duration (QRS), PR interval (PR), QT interval (QT), resting heart rate (RR), SokolowLyon voltage (SLV) and Cornell voltage (CLV). The heritability of each trait was
calculated in two ways: under a classical polygenic model using nuclear families in
SOLAR (Almasy, 1998) and by calculating the fraction of phenotypic variance explained
by the empirically estimated kinship matrix in EMMAX (Kang, 2010). The latter is
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Trait1
Total cholesterol
(mg/dL)
Low density lipoprotein cholesterol4
(mg/dL)
High density lipoprotein cholesterol4
(mg/dL)
Triglycerides
(mg/dL)
Campesterol
(mg/dL) 6
Sitosterol
(mg/dL) 6
Lathosterol
(mg/dL) 6
C-reactive protein
(mg/L)
Glomular filtration rate
(mg/dL)
Uric acid
(mg/dL)
Folic acid
(ng/mL)
Homocysteine
(mg/L)
Thyroid stimulating hormone
(μIU/mL)
Height
(inches)

All2
165.98±33.9
2,717
101.71±28.93
LDL
1,870
87.1±21.07
APOB
1,834
38.19±5.87
HDL
1,873
116.87±24.20
APOA-1
1,834
103.03±46.23
2,718
1.36±0.57
2,135
1.23±0.54
2,135
1.19±0.58
2,135
0.282±0.349
1,852
101.95±24.33
1,872
5.46±1.47
1,844
9.79±3.36
1,857
5.76±2.01
1,845
1.60±0.91
1,834
62.21±3.21
2,354

Males2
165.16±35.4
1,122
102.37±31.16
711
89.72±21.19
766
33.33±9.16
709
108.23±21.76
765
112.79±53.38
1,122
1.34±0.67
974
1.20±0.72
974
1.18±0.64
974
0.268±0.345
697
96.81±25.23
708
6.3±1.45
694
8.98±3.04
699
6.82±2.13
696
1.66±0.94
705
65.12±2.1
950
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Female2
116.56±32.79
1,595
101.39±27.66
1,159
85.21±20.79
1,068
41.18±10.49
1,164
123.13±23.78
1.069
96.4±39.73
1,596
1.37±0.74
1,161
1.25±0.61
1,161
1.19±0.59
1,161
0.293±0.356
1,155
105.27±24.17
1,164
4.96±1.23
1,150
10.3±3.52
1,158
5.14±1.71
1,149
1.57±0.91
1,129
60.10±2.17
1,404

Covariates3 h2(SOLAR)

h2(EMMAX)

g,a

0.425

0.503

g,a

0.414

0.459

g,a

0.452

0.432

g,a

0.391

0.412

g,a

0.398

0.401

g,a

0.274

0.352

g,a

0.423

0.451

g,a

0.412

0.414

g,a

0.442

0.501

g,a,b

0.245

0.346

g,a

0.170

0.205

g,a

0.420

0.475

g,a

0.210

0.286

g,a

0.160

0.206

g

0.272

0.509

g,a

0.790

0.844

Weight
172.23±34.12
180.92±34.24
165.34±33.12
g,a
0.520
0.586
(lb)
2,321
949
1,372
Waist circumference
37.43±4.99
37.2±4.5
37,81±5.13
g,a
0.430
0.360
(inches)
2,356
955
1,401
Body mass index
31.46±5.87
30.28±5.34
32.29±6.15
g,a
0.473
0.521
(kg/m2)
2,358
956
1,402
Percent body fat
30.37±9.81
20.97±7.65
35.87±6.54
g,a
0.414
0.485
(%)
1,578
598
980
Leptin hormone levels
24.11±20.16
11.46±11.01
31.18±20.34
g,a
0.196
0.251
(ng/mL)
2,808
1,166
1,642
Fasting blood sugar
85.34±8.12
85.45±8.41
85.27±7.81
g,a,b
0.188
0.180
(mg/dL)
1,456
624
832
HBA1C
6.03±2.03
6.14±2.05
5.97±2.01
g,a
0.204
0.223
(%)
2,034
768
1,266
Systolic blood pressure
117.23±17.02
120.34±12.61
115.34±17.32
g,a,b
0.243
0.298
(mmHg)
2,402
967
1,435
Diastolic blood pressure
77.25±10.45
79.6±10.13
75.04±10.12
g,a,b
0.289
0.346
(mmHg)
2,402
967
1,435
Table 5.2 Phenotype characteristics. For each trait; the mean±standard deviation of the raw phenotype, and the number of all phenotyped individuals (All), the
mean±standard deviation of the raw phenotype, and the number of male phenotyped individuals (Male), the mean±standard deviation of the raw phenotype, and
the number of female phenotyped individuals (Female), any covariates that were adjusted for (Covariates), heritabilites as calculated using a polygenic model in
SOLAR (h2(SOLAR)) and by the fraction of heritability explained by the phenotypic variance in the relatedness metrix in EMMAX (h 2(EMMAX)).
1

Trait: the trait (units of measurement)
Mean±standard deviation, number of phenotyped samples used in the analysis
3
Covariates; g=gender, a=age, b=bmi
4
For the 1994 screen, LDL and HDL quantification was not possible due to the lack of an adequate centrifuge on the island and the inability to ship serum
overnight at 4 C. As substitutes, the major apolipoproteins of LDL and HDL (APOB (mg/dL), and APOA-I (mg/dL), respectively) were measured using a
standard double antibody immunoassay. Both APOB and APOA-I are highly correlated with their respective cholesterol fractions, making them excellent
surrogates. For 1,081 individuals who were screened in both 1994 and 2001, the average of their Z-scores for the both measurements was used.
5
The distribution of Lipoprotein(a) levels was tri-modal, and raw values with no normalization were used in the association mapping
6
Plasma plant sterols (Campesterol, Sitosterol and Lathosterol) are give as a ratio with Total Cholesterol
2
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designated “psuedoheritability” since the estimated pairwise relatedness does not
correspond exactly to the kinship coefficients. Nonetheless, the EMMAX heritability
estimates are concordant with the heritability estimates from the nuclear families (r2>0.9).
The details of the phenotypes, including population means and covariate adjustments
heritability estimates for the metabolic traits, are given in Table 5.2 Electrocardiographic
measures are also given (Lowe, 2009, Smith, 2009).

Results

from

the

genome-wide

association

analysis

of

30

metabolic

and

electrocardiographic traits.

Based on our observations from the simulated data (see Chapter 4), we selected the
mixed model method as the most powerful method for analyzing our study population.
We first built a kinship matrix of pairwise identity-by-state metrics based on high-density
markers for the entire pedigree, which was then incorporated into the mixed model for
association mapping (Kang, 2010). We had previously published the results of the
genome-wide association analysis of 17 of these traits using the PLINK/QFAM-total
framework (Lowe, 2009, Smith, 2009). Here, we re-analyzed data for these 17 published
phenotypes using the EMMAX framework, along with another 13 previously unreported
phenotypes from the island.
.
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Symbol
TC
LDL
HDL
TG
CMP1
SIT1
LAT1
CRP
GFR
URT
FLT
HOMO
TSH
HGT
WT
WST
BMI
PCF
LEP
FBS
HBA1C
INS
SBP
DBP
RRD
PRD
QRS
CLV
SLV

Trait
Total cholesterol
Low density lipoprotein cholesterol
High density lipoprotein cholesterol
Triglycerides
Campesterol:Cholesterol
Sitosterol:Cholesterol
Lathosterol:Cholesterol
C-reactive protein
Glomular filtration rate
Uric acid
Folic acid
Homocysteine
Thyroid stimulating hormone
Height
Weight
Waist circumference
Body mass index
Percent body fat
Leptin hormone levels
Fasting blood sugar
Haemoglobin A1C
Insulin sensitivity
Systolic blood pressure
Diastolic blood pressure
Resting rate interval
PR interval
QRS interval
Cornell voltage
Sokolow-Lyon voltage

#SNPs
354,880
354,901
354,005
354,250
323,674
323,437
323,391
329,883
329,414
323,483
323,869
323,775
354,558
354,661
354,213
354,290
352,213
323,923
323,797
348,036
324,031
340,724
353,640
353,640
340,312
346,566
346,710
346,710
346,710

λ
1.0044
0.9785
0.9714
1.0066
1.0103
1.0029
1.0034
1.0220
0.9894
1.0064
0.9945
1.0123
1.0170
0.9756
0.9690
0.9876
0.9599
0.9947
0.9872
1.0135
1.0122
0.9975
1.0292
1.0088
1.0092
1.0188
1.0159
1.0082
1.0160

Table 5.3 Number of SNP’s tested for each trait and estimate of p-value score inflation. For each trait;
the number of >0.01 MAF SNP's per phenotype (#SNP's) and genomic control correction factor (λmedian)
from the p-value distribution from the EMMAX association mapping (Devlin, 1999).
1

The λ for the three plasma plant sterol traits was calculated after the removal of the SNP‟s comprising the
broad peak around the top SNP (Chr2:36-47MB), see chapter 3 for details.

We observe minimal score inflation using the EMMAX method where the inflation factor
 is estimated to be in the range from 1.03 to 0.96 for all traits (see Table 5.3). This is in
contrast with previously reported  values that are significantly greater than 1 for a subset
of the traits analyzed using PLINK/QFAM -total ( range: 2.05 – 1.10)(Lowe, 2009). We
noted that genome-wide analysis with =1.1 inflation of p-values results in a 4.8-fold
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increase in the expected number of false-positive results attaining genome-wide
significance, with practical implication for the feasibility of follow-upTable 5.4 provides
the top SNP per region emerging genome- and study-wide significant from the EMMAX
analysis of all 30 traits. We determined a genome-wide significance threshold based on
~310K effective independent tests (~350k-320k actual tests) to be 1.6x10-7 (see
Materials and Methods).
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Trait
TC
LDL

HDL

TG
CRP

HOMO
TSH
HGT
URT
QT
HBA1C
PPS

N1

CHR:POS2

Top SNP

A13

MAF

effect size
β5

s.e.

% var7

p-value

Gene region8

6

2,753
19:45.4

rs4420638

G/A

0.182

0.274

0.033

2.42

1.47x10-17

APOE

19:45.4
5:74.7

rs4420638(+1)
rs3846663

G/A
T/C

0.182
0.197

0.316
0.210

0.033
0.029

3.24
1.93

2.57x10-23
8.81x10-7

APOE
HMGCR

16:57.0
19:45.4

rs1800775
rs4420638

A/C
G/A

0.394
0.182

0.183
-0.198

0.026
0.033

1.82
1.16

7.03x10-9
6.30x10-7

CETP
APOE

11:116.7

rs7396835(+6)

T/C

0.372

0.214

0.026

2.36

2.42x10-12

APOA5/APOCIII

19:45.4
1:159.7

rs4420638
rs3093077(+4)

G/A
C/A

0.182
0.247

-0.318
0.245

0.041
0.037

3.05
2.25

6.16x10-13
7.10x10-9

APOE
CRP

11:89.3

rs1836883

T/C

0.321

0.210

0.036

1.75

1.29x10-8

NOX4

9:100.5

rs1877431(+19)

A/G

0.224

-0.299

0.037

3.46

6.32x10-14

FOXE1

17:43.0

rs17629022

C/T

0.064

0.481

0.058

2.83

2.00x10-8

GFAP

11:63.9

rs2186571(+58)

A/G

0.028

-1.433

0.101

9.79

1.77x10-34

URAT19

21:34.7

rs2070359(+1)

A/C

0.373

-0.226

0.032

2.35

5.17x10-9

KCNE1

16:89.0

rs2968474

A/C

0.224

-0.309

0.021

3.05

7.20x10-9

CBFA2T3

2:44

rs12185607

A/C

0.11

1.34

0.121

10.32

3.21×10-31

ABCG5/ABCG8

2,775

2,774

2,754
1,872

1,870
1,858
2,364
1,861
1,432
1,860
2.034
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Table 5.4 Genome- and study-wide significant SNPs from the analysis of 30 traits.This table lists the top SNP in a genetic region for the association of 25
traits pertaining to metabolic syndrome and electrocardiographic conductance that surpasses genome-wide significance (p≤ 1.6x10-7). SNP’s that also surpassed
study-wide significance (p≤ 6.4x10-9) are indicated in italics.
1

N; the number of phenotyped individuals for the trait
POS(MB): chromosomal physical position in megabases; Genome Reference Consortium build 37 (GRCh37)
3
A1; the minor allele
4
A2: the major allele
5
β; the effect size (linear mixed model regression coefficient)
6
s.e.; the standard error of the effect size
7
%var; the percent variance explained (oneway ANOVA)
8
Candidate genes in the region of the top SNP
9
rs2186571 is > 400kb upstream of URAT1 (see results section for explanation)
2
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Observation of positive controls in the Kosare dataset

As positive controls, we observed associations to ten genomic regions for ten traits
exceeding our genome-wide significance threshold. Top SNPs are in or near to known
loci for plasma cholesterol (APOE; rs4420638, p ≤ 1.47x10-17), high density lipoprotein
(CETP; rs1800775, p ≤ 7.03x10-9), low density lipoprotein (APOE; rs4420638, p ≤
1.47x10-23), triglycerides (APOC3/A5; rs7396835, p ≤ 2.42x10-12), thyroid stimulating
hormone (FOXE1; rs1877431, p ≤ 6.32x10-14), homocysteine (NOX4; rs1836883,
p≤1.3x10-8), C-reactive protein (APOE; rs4420638, p ≤ 6.16x10-13 and CRP; rs3093077,
p ≤ 7.10x10-9), QT interval (KCNE1; rs2070359, p ≤ 5.2x10-9) and the plasma plant
sterols (ABCG5/ABCG8; rs12185607, 3.21×10-31) (Kathiresan, 2009, Kathiresan, 2008,
Elliott, 2009, Willer, 2008, Sandhu, 2008, Gudmundsson, 2009, Pare, 2009). Nine of
these regions are shown in detail in Figure 5.1A (for details regarding the plasma plant
sterol region, see Chapter 2). Furthermore, six of these signal peaks surpassed our studywide significance threshold of 6.4x10-9 (see Material and Methods). Only one of these
positive controls had been detected at genome-wide significance in the previous analysis
of the same traits: triglycerides (APOC3/A5; rs7396835, p ≤ 1.2x10-9) (Lowe, 2009). In
addition we observed two other known positive controls significant at FDR <0.3: low
density lipoproteins (HMGCR; rs3846663, p ≤ 8.77x10-7) and high density lipoprotein
(APOE; rs4420638, p ≤ 6.33x10-7)(Kathiresan, 2009, Aulchenko, 2009).

86

Novel findings from the Kosrae association mapping

As novel findings, we observed three interesting genome-wide significant signals, one
strong signal for uric acid levels that resides >500kb upstream of two independent known
associations (rs2186571, p<1.8x10-34), and signals for height and HBA1C which
represented a novel association in the Kosraen cohort (rs17629022, p<2.1x10-8; and
rs2968474, p<7.2x10-9, respectively; see Figures 5.1B and 5.1C).
The novel SNP rs17629022 for height has a minor allele frequency of 0.06 and a strong
effect size of 0.48 standard deviations per allele (for normalize z-scores, μ=0, σ=±1). This
corresponds to an average 1.28” (95% confidence intervals: 0.97”-1.66”) and 4.23” (95%
confidence interval: 2.48”-5.97”) average increase in height in carriers (n=271) and
minor allele homozygotes (n=13), respectively, compared to major allele homozygotes.
The SNP resides on chromosome 17q21 in a gene rich region containing GAP, CCDC103
and FAM187A.
The novel SNP rs2968474 for HBA1C has a minor allele frequency of 0.224 and a strong
effect size of -0.309 standard deviations per allele. In work by my collegue, Sasha Gusev,
the signal for this SNP was fine mapped to a 200kb, 11 SNP haplotype in the region
(p<1.66x10-23), where the HBA1C haplotype carriers (n=284) and homozygotes (n=8)
have decreased HBA1C levels, 5.00%±0.57% and 4.13%±0.51%, respectively, compared
to non-carriers (n=1,282), 5.33%±0.53%. Further, low pass sequencing in the region
provide preliminary evidence for both coding mutations in genes on the background of
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Figure 5.1 Eleven regions of genome-wide significant associations. (A) We observe nine genome-wide
significant associations to known loci for plasma cholesterol, high density lipoprotein, low density
lipoprotein, triglycerides, thyroid stimulating hormone, homocysteine, C-reactive protein and QT interval
(the tenth positive control, ABCG8/G5 region for PPS is described in Chapter 2). (B) Region of novel
association for height and haemoglobin A1C. The y-axis show’s –log10p-value (LOD) and the x-axis shows
the chromosomal physical position in megabases. The maroon square represents the location of the top
scoring SNP. The red and pale blue dashed lines indicate the genome- and study-wide significance
thresholds, respectively.
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the haplotype and structural variation in carriers. This work is currently under preparation
for publication (pers. comm. Sasha Gusev). Analysis of the uric acid trait revealed a
broad peak in the genome scan on chromosome 11q13.1 (59.2-65.3 MB) containing 54
SNPs that surpassed the study-wide significance threshold (Figure 5.3C). The top SNP,
rs2186571, represents a novel association to uric acid. Further, the very low p-value of
the top SNP p<1.8x10-34, signifies an effective internal replication of the signal, since, for
an effect this strong, a genome-wide significant signal would be observed in any
randomly partitioned half of the study population. rs2186571/A has a minor allele
frequency of 0.028 and a strong effect size of -1.14 standard deviations per allele,
accounting for ~10% of uric acid level variance on Kosrae, where carriers of
rs2186571/A have a mean uric acid level of 3.6 mg/dL compared to the major allele
homozygotes level of 5.5 mg/dL. However, rs2186571 resides ~500kb upstream of two
variants on chromosome 11q13.1 recently found to be associated with uric acid levels
(Kolz, 2009). To determine whether the strong uric acid signal represented a novel
observation or might tag either of the previously observed signals, we performed a
haplotype-based fine-mapping of the signal region and conditional analysis.

Fine mapping the interval of uric acid association

Haplotype mapping has been previously described in Chapter 2. Briefly, common shared
long-range haplotypes were detected via pair-wise IBD genetic segment matching
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between all individuals in the pedigree using the GERMLINE software (Gusev, 2009).
The IBD segments were at least 3cM in length and allowed for up to 1% mismatching
due to genotyping error.

IBD segments were then clustered to groups of similar

haplotypes, with >500kb overlapping sequence and sharing >99% sequence identity, as
described in detail previously (Kenny, 2009). Clusters of shared haplotypes were then
independently mapped to uric acid levels which identified a single strong mapping
cluster, where the specific sharing boundaries of the haplotype mapped to a ~2MB subregion (chr11:63.7-65.5) of the uric acid GWAS signal peak (see Figure5.2(A)). This
"uric acid haplotype" (rs4980499 to rs1074156) is unique to a group of 96 individuals
(carrier frequency 0.03), is strongly associated to uric acid (p<9.07x10-46), and has an
effect size of -2.12 standard deviations per allele (accounting for ~20% of uric acid level
variance on Kosrae; 95% confidence intervals 16.8%-21.6%). Conditioning the uric acid
levels for the uric acid haplotype effect abolishes signal at the rs218571 SNP (p<0.83),
whereas, a significant signal remains (p<2.1x10-5) at the uric acid haplotype when the
levels are adjusted for the effect of rs218571 (see Table 5.5). Genome-wide scan of
haplotype conditioned uric acid levels reveals no remaining genome-wide significant
signals (see Figure 5.2(B)). Therefore, the uric acid haplotype likely captures the full
signal tagged by the top GWAS SNP.

We next determined whether the uric acid haplotype represented a novel variant or a
refinement of one or both loci that had previously shown uric acid variants, rs17300741
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and rs505802. The two known variants reside in/near organic ion transporter 4 (OAT4)
and urate transporter 1 (URAT1), respectively, which are known candidate genes for renal
urate anion exchange and are thought to regulate blood uric acid levels (Taniguchi, 2008,
Ekaratanawong, 2004).

Neither variant was directly assayed in the Kosrae genotype

panel. However, two assayed variants on the 500k Affymetrix chip, rs12362644 and
rs10897518 that flank rs17300741 and rs505802, respectively, were observed to be in
complete linkage disequilibrium (r2=1) with each variant in all HapMap Asian panels
(CHB, CHD, JPT, GIH). We therefore concluded that rs12362644 and rs10897518
genotyped on Kosrae would be strong tags for the unobserved rs17300741 and rs505802
variants, respectively. Indeed, signals for association were observed for rs12362644 (p <
8.16x10-5) and rs10897518 (p < 3.41x10-17), the latter being study-wide significant.

Analysis of the uric acid haplotype conditioned on rs12362644 and rs10897518 abolished
the signal at these two variants (p<0.41 and p<0.93, respectively). However, the strong
signal at the uric acid haplotype persisted (p< 8.48x10-23). Conversely, when uric acid
levels are conditioned on the uric acid haplotype, moderate signal for rs12362644
(tagging rs17300741) remained 2.66x10-3; however, signal at rs1087518 (tagging
rs505802) was abolished (p<0.94) (see Table 5.5), indicating that, while there is some
correlation between rs12362644 and the uric acid haplotype, the haplotype effect is not
explained by the effect of rs12362644. Instead, this effect is the result of the variant
tagged by rs10897518, which is carried on the uric acid haplotype background.
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Figure 5.2 Conditioning on the URT haplotype. (A) Chromosome 11q13 region of association to uric
acid levels before and after conditioning uric acid levels on the uric acid haplotype. (B) QQ plot showing
genome-wide association to uric acid levels and to uric acid levels conditioned on the uric acid haplotype.
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naïve score

URT Haplotype

rs12362644
(tagging rs17300741)

rs10897518
(tagging rs505802)

9.07 x10-46

8.16x10-5

3.41x10-17

-

2.66x10-3

-

-

4.94x10-16

Adjusted allele(s)
URT Haplotype

-44

rs12362644

4.71x10

rs10897518

8.56x10-24

1.06x10-3

-

8.48x10-23

-

-

rs12362644
rs10897518

and

Table 5.5 Conditional analysis. Conditional analysis of the URT haplotype, rs12362644 (tagging
rs17300741) and rs10897508 (tagging rs505802) at the uric acid locus on chromosome 11q13.1

Moreover, comparing the 0.06 frequency of rs1087518 on Kosrae to the lower 0.015
frequency of the uric acid haplotype indicated a refinement of the signal by a factor of 4,
dramatically reducing the sequence and sample search space for pinpointing the
underlying causal variant.

Comparison of effect sizes for known associated loci

We observe that for common variants that are polymorphic in Kosrae, this cohort often
achieves significant association, with significantly stronger statistical support than its
sample size would suggest. A good example for that is the LDL phenotype, where ~2,800
phenotyped islanders are sufficient

to detect positive controls signals – known
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associations on chromosomes 19 (APOE) and 5 (HMGCR) are significant at levels
<310-22 and <910-7, respectively. We extrapolated from reports in cohorts from
European populations (Kathiresan, 2008, Aulchenko, 2009) that >10000 samples are
needed to expose these associations at this significance level. Comparing the association
regression coefficients () shows a larger increase on the normalized phenotype in
Kosrae.

To more formally examine the genetics of common traits on Kosrae as compared to
outbred populations, we assessed the effect sizes of known loci observed in our study.
Specifically, we identified 53 established associations in large, mainly Caucasian studies
across seven traits (BMI, CRP, HDL, HGT, LDL, TG and URT), where the associations
had sufficiently high effect size and/or allele frequency to be detectable at nominal
significance

in

the

~3,000-strong

Kosrae
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study

(see

Table

5.6)

Trait
BMI
BMI
CRP
CRP
CRP
CRP
HDL
HDL
HDL
HDL
HDL
HDL
HDL
HDL
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT
HGT

SNP
rs9939609
rs17782313
rs4420638
rs7310409
rs7553007
rs4129267
rs1800775
rs328
rs7395662
rs4939883
rs2271293
rs3890182
rs2156552
rs4846914
rs6763931
rs724016
rs798544
rs3748069
rs2282978
rs4533267
rs6060369
rs1812175
rs7153027
rs2562784
rs7846385
rs1042725
rs4743034
rs10513137
rs3760318
rs6918981
rs4794665

Gene/Region
FTO
MC4R
APOE
HNF1A
CRP
IL6R
CETP
LPL
MADD-FOLH1
LIPG
CTCF-PRMT8
ABCA1
LIPG
GALNT2
ZBTB38
ZBTB38
GNA12
GPR126
CDK6-GATAD1
ADAMTS17
GDF5-UQCC
HHIP
TRIP11-ATXN3
SH3GL3-ADAMTSL3
PXMP3-ZFHX4
HMGA2
ZNF462
ZBTB38
CRLF3-ATAD5
HMGA1
NOG-DGKE

Allele1
A
C
G
A
A
A
C
G
G
A
G
A
A
G
A
G
G
A
C
A
C
C
A
G
C
T
A
A
C
G
A

Outbred
Freq Beta
0.45 0.1
0.28 0.05
0.18 -0.21
0.39 -0.15
0.33 -0.2
0.4
-0.1
0.43 -0.18
0.13 0.17
0.61 -0.073
0.83 0.07
0.87 -0.129
0.09 -0.1
0.2
-0.07
0.42 -0.07
0.48 0.07
0.48 0.37
0.72 0.06
0.73 0.07
0.37 0.06
0.28 0.06
0.36 0.44
0.81 0.08
0.61 0.06
0.17 0.34
0.34 0.05
0.49 -0.48
0.24 0.05
0.26 0.03
0.64 0.06
0.21 0.02
0.53 0.04

P-value
2.00E-20
2.80E-15
5.00E-27
6.80E-17
1.10E-26
2.00E-08
1.00E-73
9.00E-23
6.00E-11
2.40E-07
8.30E-16
3.00E-10
2.00E-07
2.00E-13
1.40E-27
8.30E-22
6.50E-15
4.50E-14
9.80E-09
3.30E-08
1.40E-16
9.70E-12
1.10E-10
6.40E-08
4.70E-08
2.70E-20
2.10E-08
8.00E-08
1.80E-09
2.00E-08
9.90E-08
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On 500K?2
same
same
same
rs2393791
same
rs4537545
same
rs10503669
same
same
same
same
same
same
rs6440003
rs6440003
same
rs7755109
same
same
same
same
same
same
same
same
rs12411264
same
rs7225461
same
same

Kosrae
Freq
0.12
0.08
0.21
0.44
0.38
0.36
0.58
0.98
0.43
0.64
0.6
0.37
0.03
0.58
0.25
0.25
0.47
0.25
0.06
0.4
0.31
0.63
0.77
0.42
0.16
0.55
0.14
0.09
0.56
0.14
0.26

Beta
0.13
-0.04
-0.32
-0.139
0.111
-0.097
-0.169
0.247
-0.05
0.084
-0.06
-0.03
0.07
0.0009
0.105
0.105
0.078
0.082
-0.141
-0.0588
-0.06
0.05
-0.059
0.043
-0.05
0.022
0.03
0.03
-0.0158
0.018
-0.008

P-value
3.00E-02
5.70E-01
6.50E-13
2.84E-04
3.90E-03
8.56E-03
7.58E-09
1.03E-02
1.21E-01
2.16E-01
2.29E-01
2.60E-01
2.80E-01
7.45E-01
3.17E-03
3.17E-03
1.23E-02
3.76E-02
3.80E-02
6.90E-02
7.20E-02
1.13E-01
1.41E-01
1.89E-01
2.58E-01
5.02E-01
5.57E-01
5.60E-01
6.44E-01
6.90E-01
8.13E-01

Study3
Frayling(2007)
Loos(2008)
Ridker(2008)
Ridker(2008)
Ridker(2008)
Ridker(2008)
Kathiresan (2008)
Kathiresan (2008)
Aulchenko(2009)
Aulchenko(2009)
Aulchenko(2009)
Kathiresan (2008)
Kathiresan (2008)
Kathiresan (2008)
Gudbjartsson (2008)
Lettre(2008)
Gudbjartsson (2008)
Gudbjartsson (2008)
Gudbjartsson (2008)
Gudbjartsson (2008)
Lettre(2008)
Gudbjartsson (2008)
Gudbjartsson (2008)
Lettre(2008)
Gudbjartsson (2008)
Lettre(2008)
Gudbjartsson (2008)
Kim(2009)
Gudbjartsson (2008)
Kim(2009)
Gudbjartsson (2008)

HGT rs6830062
LCORL-NCAPG
T
0.84 0.06
1.30E-10
same
0.94 0.016
HGT rs967417
BMP2
C
0.57 0.04
1.50E-08
same
0.13 -0.006
LDL rs4420638
APOE
G
0.18 0.19
1.00E-60
same
0.21 0.365
LDL rs12654264 HMGCR
T
0.42 0.1
1.00E-20
same
0.42 0.133
LDL rs157580
APOE
G
0.33 -0.111
2.10E-19
same
0.32 0.0326
LDL rs16996148 CLIP2-PBX4
T
0.06 -0.1
3.00E-08
same
0.17 -0.05
LDL rs693
APOB
A
0.49 0.12
1.00E-21
same
0.09 -0.026
LDL rs174570
FADS2/3
G
0.83 0.11
4.40E-13
same
0.80 -0.0003
TG
rs16996148 CILP2-PBX4
T
0.06 -0.1
4.00E-09
same
0.17 -0.179
TG
rs780094
GCKR
T
0.38 0.13
3.00E-14
same
0.27 -0.125
TG
rs17321515 TRIB1
G
0.4
-0.08
4.00E-17
same
0.7
-0.0928
TG
rs328
LPL
G
0.13 -0.19
1.00E-28
rs10503669 0.98 0.143
TG
rs157580
APOE
G
0.33 -0.069
1.20E-08
same
0.32 -0.034
TG
rs12130333 DOCK7
T
0.24 -0.11
2.00E-08
same
0.04 -0.07
TG
rs693
APOB
A
0.49 0.08
2.00E-07
same
0.09 -0.05
TG
rs4846914
GALNT2
G
0.42 0.08
7.00E-15
same
0.58 -0.022
TG
rs10889353 DOCK7
C
0.32 -0.085
8.20E-11
same
0.23 0.023
TG
rs17145738 MLXIPL
T
0.12 -0.14
7.00E-22
same
0.14 -0.029
URT rs505802
SLC22A12
T
0.7
-0.06
2.00E-09
rs10897518 0.97 -0.64
URT rs17300741 SLC22A11
A
0.51 0.06
7.00E-14
rs12362644 0.71 0.162
URT rs780094
GCKR
T
0.42 0.05
1.00E-09
same
0.18 -0.082
URT rs1165205
SLC17A3
T
0.46 -0.09
4.00E-27
same
0.23 0.04
Table 5.6: Comparison of effects and allele frequencies in Caucasians and Kosraens for known associated loci.
1

8.34E-01
9.14E-01
1.13E-23
1.66E-05
3.49E-01
5.63E-01
6.43E-01
9.50E-01
2.11E-05
1.15E-03
7.04E-03
1.51E-01
3.30E-01
3.48E-01
3.63E-01
4.60E-01
5.06E-01
8.20E-01
3.14E-17
8.16E-05
9.73E-02
3.50E-01

Gudbjartsson (2008)
Gudbjartsson (2008)
Kathiresan (2008)
Kathiresan (2008)
Aulchenko(2009)
Kathiresan (2008)
Kathiresan (2008)
Aulchenko(2009)
Kathiresan (2008)
Kathiresan (2008)
Kathiresan (2008)
Kathiresan (2008)
Aulchenko(2009)
Kathiresan (2008)
Kathiresan (2008)
Kathiresan (2008)
Aulchenko(2009)
Kathiresan (2008)
Kolz(2009)
Kolz(2009)
Kolz(2009)
Dehghan(2008)

Allele: the effected allele
On 500K?: if the SNP from the outbred population study is on the 500K Affymetrix chip used in the Kosrae study “same” is indicated. If not, then a proxy SNP
(r2>0.95 between the proxy SNP and the outbred population SNP) that is on the 500K Affymetrix chip is listed.
3
Study: The outbred population studies used for this analysis are given in the references (Frayling, 2007)(Loos, 2008)(Ridker, 2008)(Kathiresan,
2008)(Aulchenko, 2009)(Lettre, 2008)(Gudbjartsson, 2008)(Kim, 2010)(Kolz, 2009)(Dehghan, 2008)
2
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(Lettre, 2008, Kathiresan, 2008,
Frayling, 2007, Loos, 2008,
Ridker, 2008, Aulchenko, 2009,
Gudbjartsson, 2008, Kim, 2010,
Kolz, 2009, Dehghan, 2008).
For SNP‟s not directly typed on
the

Figure 5.3 Comparison of effect sizes for known loci in
outbred populations on Kosrae. Effect sizes (the linear mixed
model regression coefficient) on Kosrae (Kos on the y-axis) and
in outbred populations (EU on the x-axis) for 16 genome-wide
significant SNP’s from outbred population studies, where the
signals are nominally significant on Kosrae and in the same
direction, are plotted. A fitted line shows the cases where the
effect size is stronger in the outbred population (blue) and on
Kosrae (red)

Affymetrix

array,

association results are reported
for a proxy on the Affymetrix
chip with strong correlation
(r2>0.95) to the original SNP in
both HapMap Caucasian (CEU)

and Asian (CHB, CHD, JPT, GIH) panels. Of the 53 SNP‟s, only 21 were detectable on
Kosrae at nominal significance, indicating that more than half the associated SNP‟s were
tagging causal variants that were either too rare to be detected or not present on the
Island. Sixteen of the 21 detectable SNP‟s on Kosrae had effect sizes in the same
direction as those SNP‟s in the Caucasian cohorts (p<0.01) and 5 were in the opposite
direction. Of the former set of 16 SNP‟s, 12 had stronger effect sizes on Kosrae, which is
a greater number than expected by chance (p<0.027)
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Discussion

We describe a GWAS in a population-based cohort with extensive family structure and
explore the value of genetics studies in a extreme populations isolate. Our goal was to
take advantage of the population genetic features such a population offer, while
maximizing power to detect association using mixed models. The analysis and re-analysis
of 30 biomedical traits from the island using the more powerful mixed-model approach
yielding 13 significant hits, only one of which had been detected by other methods. More
importantly, were the discovery of a putative novel association for height, HBA1C and a
novel long shared haplotype that accounts for ~20% variance in uric acid levels on the
Island.

These three novel associations exemplify both the limitations and opportunities for
performing genetic mapping in isolated populations. We have demonstrated association
for height in a region not previously observed, despite multiple large-scale genetic studies
in Caucasians (Hirschhorn, 2009, Lettre, 2008, Weedon, 2008). It is possible that the
underlying mutation is of stronger effect or higher frequency on the island, making it
easier to detect. Alternatively, the causal variant may be Asian specific, or even private to
the island. If the latter case is true, then the signal is unlikely to be confirmed by
replication. It should also be noted that the signal for the height SNP did not reach studywide significance and could represent a false positive.
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On the other hand, we have observed a moderate signal for HBA1C (described elsewhere
– pers. comm. Sasha Gusev) and an extremely strong signal for uric acid level, both also
present in outbred, Caucasian populations, which we could refine by a IBD-based
haplotype fine-mapping facilitated by the abundance of long shared haplotypes in
isolated populations (Bonnen, 2006 ,Kolz, 2009). Further, since the uric acid haplotype
tags only one of the two Caucasian variants in the same region previously known, our
findings support independence between the two reported signals in the region. Finally,
the strong effect size of the haplotype is beyond the combined effects of variants
affecting uric acid level previous discovered (Kolz, 2009, Dehghan, 2008).

In conclusion, it is worthwhile reviewing our work in the context of recent ideas and
results in association analysis. Specifically, the emerging picture is that despite
comprehensive scans of association with common SNPs of multiple complex phenotypes,
only a limited fraction of their heritable component has been identified(Frazer, 2009,
Hindorff, 2009). Expanding the search for associated alleles to variants that are rare in the
general population provides another piece of this heritable component, with multiple gene
sequencing studies implicating such variants with moderate to high penetrance
(Fearnhead, 2004 ,Cohen, 2004 ,Kotowski, 2006 ,Romeo, 2007, Marini, 2008). Our
experiences in association testing in an isolated population can serve as a model for other
studies of similar cohorts. Methodologically, mixed-models optimally extract association
information from such samples. More importantly, in terms of study design and choice of
cohort, we observe some of the previously theorized advantages and limitations of
isolated populations. We showed that some variants that are associated to traits in other
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populations do not replicate on Kosrae and this was due to bottleneck effects rather than
lack of power. On the other hand, observed associations show strong effects and
statistical support for a cohort of this size, potentially due to increased genetic and
environmental homogeneity. Finally, as GWAS cohorts increase in size to the 6-digit
range, and inclusion of somewhat related individuals becomes a practical modus
operandi, results in this work are expected to become relevant to a wide range of
populations.
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Chapter 6 Genotypic and Haplotypic mapping of Crohn’s Disease in
Ashkenazi Jews

Introduction

Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract,
which is thought to result from the effect of environmental factors in a genetically
predisposed host. An epidemiological feature of CD is that it has highest prevalence
among individuals of Ashkenazi Jewish (AJ) descent, occurring two to four times more
frequently than in non-Jewish Caucasian populations. Three coding variants of the NOD2
gene have been reported as independent disease-predisposing mutations for CD.
Confirmation studies have shown, however, that these susceptibility loci have similar
allele frequencies and magnitudes of the effect and are unlikely to contribute to the
excess prevalence of the disease in the AJ population. Therefore, involvement of other,
yet unknown, genetic variants unique to this population is hypothesized (Sugimura,
2003).

Here we analyzed CD in seven Ashkenazi Jewish cohorts, under a combined-analysis
strategy. We generated a population specific reference panel for this dataset and impute
m. As positive controls, we observed two genome-wide and six strongly significant
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associations with known loci for Crohn‟s disease. In addition, we refined a broad signal
peak for Crohn‟s disease at the NOD2 locus on chromosome 16 using analysis of
identity-by-descent (IBD) shared genetic segments. We identified a second 13% carrier
frequency haplotype ~1MB upstream of the top SNP in the region, which is independent
of the top SNP.

Results

Sample Ascertainment
We performed a populationNY1
NY2
NY3
NY4
NY5
NY6
TA1
Total

Ntotal

NCD cases

Nnon-CD cases

Ncontrols

Platform

828
59
136
173
1,067
651
397
3,311

397
59
136
113
261
966

806
200
1,009

431
60
651
197
1,339

Illumina 300k
Illumina 1M
Illumina 550k
Affymetrix 500k
Affymetrix 6.0
Affymetrix 6.0
Illumina 300k

based screen of Ashkenazi
Jewish (AJ) individuals by
combining six New Yorkbased and one Israel-based
screenings - see Table 6.1.

Table 6.1 Study participants from nine groups successfully
genotyped on either an Illumina or Affymetrix platform.
Screenings in nine centers based in New York (NY1-7) or Israel
(TA1). For each screen, the total number of individuals examined is
shown (Ntotal), in addition to any Crohn’s disease cases (NCD_cases),
non-Crohn’s disease cases, which are a mix of Parkinson’s disease,
Schizophrenics, Type-II Diabetes and Dystonia cases, (Nnon-CD_cases),
and non-diseased controls (Ncontrols). . For each cohort, the platform
used for genotyping is shown (Platform).

Self–reported

family

relationships were recorded
and only individuals who
self-identified as AJ (or had

at least one AJ grandparent) were used in the study. The cohorts comprised samples
from; the NIDDK IBD genetics consortium, only persons with Jewish ancestry, obtained
from dbGAP (Study accession: phs000130.v1.p1) -- NY1; Yale University (pers. comm.
102

Judy Cho) -- NY2; the Children‟s Hospital of Philadelphia (CHOP) (pers. comm. Hakon
Hakonarson) – NY3; Mount Sinai Medical School (pers. comm. Inga Peters and Laurie
Ozelius) – NY4-5; Albert Einstein College of Medicine (pers. comm. Nir Barzilai) –
NY6 and the Hebrew University of Jerusalem (pers. comm. Ariel Darvasi) –TA1. The
total number of AJ individuals from the seven screens was 3,311, where 966 were
Crohn‟s disease cases and 2,345 were either non-Crohn‟s disease cases or non-diseased
controls (1,009 and 1,339, respectively).

Confirming Ashkenazi ancestry of study participants

To confirm the AJ ancestry of the all the samples in the combined cohort we performed a
principal component analysis (PCA) plotting the samples with the three continental
HapMap reference panels (CEU, YRI and ASN (combined JPT+CHB) and seven panels
from the Jewish HapMap (JHapMap) consortium consisting of one Ashkenazi Jews, one
European Jewish, three Middle Eastern and two Sephardic Jewish panels. Figure 6.1
shows the first and second eigenvectors of the PCA. Figure 6.1(A) shows the separation
the three continental groups, where all except eight of the AJ samples cluster with the
CEU Hapmap reference panel as expected. Figure 6.1(B) shows the same graph with the
outlier YRB and ASN samples removed.

~80% of individuals (n=2,661) in the AJ

sample form a distinct cluster with the Ashkenazi Jews from JHapMap along the first
principal components axis (PC1) as compared to both non-AJ Jews and individuals with
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A

B

Figure 6.1 PCA analysis of AJ samples. (A) A principal component analysis graphs showing the first (xaxis) and second (y-axis) eigenvectors plotting all 3,490 AJ samples (SAMPLE). Also included and colorcoded in the graphs are the four HapMap reference samples; CEPH-Utah (CEU), Yoruban-Nigeria (YRB)
and the combined (Han Chinese and Japanese) Asian samples (ASN); and seven Jewish samples from the
JewishHapMap project, consisting of Ashkenazi Jews (ASHKENAZI), one European Jewish (ITALIAN),
three Middle Eastern (SYRIAN, IRAQI and IRANIAN) and two Sephardic Jewish cohorts
(SEPH_TURKEY and SEPH_GREEK). (B) The same graph excluding the YRB and ASN outlier groups.

104

no Jewish ancestry (CEU), where the AJ cluster has a higher score than any other cluster.
Further, we could identify ~300 samples who were positioned between the AJ cluster and
the non-Jewish cluster (CEU) on PC1 (see Figure 6.2(A)). Upon examining the
distribution of PC1 values in these samples, three distinct modes were defined; Group 1
(PC1 -0.005-0.018), Group 2 (PC1 -0.015- -0.006) and Group 3 (PC1 -0.03- -0.016) (see
figure 6.2(B)). We postulated, based on previous PCA analysis of AJ individuals (Need,
2009) that groups 2 and 3 might represent individuals with 75% (one non-AJ
grandparent) and 50% (one non-AJ parent or two non-AJ grandparents) AJ ancestry,
respectively. So as not to exclude these individuals with partial AJ ancestry, we devised a
GWAS strategy, whereby we would perform association mapping in within each group
independently to control for admixture effects, and combined the p-values from each
group under a meta-analysis design to construct a single test score. Further, we noted
that group 3 (50% AJ ancestry) contained ~2-fold more CD cases than controls and thus

A

B

Figure 6.2 Clustering along PC1 for people with AJ (to the right) and without and Jewish (to the left)
ancestry. Samples that clustered along PC1 between the AJ cluster (bottom right) and CEU cluster
(bottom left) are shown between the dotted grey lines (A). A histogram of PC1 values for the included
samples show three distinct modes (Groups 1-3).

.
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would be under powered for detecting CD driven signal. To optimize the power in group
3, and under the assumption that group 3 comprised individuals that were 50% AJ/50%
non-Jewish ancestry, we added 100 randomly drawn controls from group 1 and 100
randomly select non-Jewish controls from the HapMap CEU population to group three.
The final count of CD cases/Controls in each group was; group 1 (100% AJ) 671/1,890,
group 2 (75% AJ) 35/37 and group 3 (50% AJ) 80/247.

Constructing an Ashkenazi genotype reference panel

Due to low imputation quality for AJ samples imputed from any of the standard HapMap
reference panels, we opted to construct a custom AJ reference panel for imputation. We
selected a random 100 AJ samples from the NY6 cohort who had been genotyped on the
Affymetrix 6.0 platform and also typed those individuals on the Illumina 1M platform.

SNP’s
SNP’s X Ind’s
Total concordance

Total
268,907
24,062,937

Discordant
15,956
31,354
0.9987

Table 6.2 SNP concordance between platforms.

The raw data consisted of 100 individuals
typed for 1,778,360 unique SNP‟s across both
platforms. To test for difference in the quality

of genotyping on the two platforms, we examined the concordance of the overlapping
SNP‟s. Of the 268,907 SNP‟s present on both platforms, >99% were concordant across
all individuals between platforms (excluding SNP‟s with 1 or 2 missing genotypes on
either platform and „ambiguous SNP‟ that are A/T or C/G on the Affymetrix platform).
Two individuals who were <99.5% concordance were excluded from the reference panel
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(see Figure 6.3(A)). In addition, 263/268,907 were <0.9 concordant between the
platform, which extrapolates to an estimated <0.0001 SNP discordance between the two
platforms (see Figure 6.3(B)). To ensure the highest quality of the AJ reference panel we

A

B

Figure 6.3 Individual (A) and SNP (B) concordance between the Affymetrix and Illumina platforms.

also excluded SNPs that were homozygous heterozygote, had a minor allele frequency
(MAF) <0.02 and a genotype missingness of >0.02. For those SNP‟s that had ≤ 0.02 SNP
missingness, we ran imputed the missing markers using BEAGLE (Browning, 2007)
across the reference panel. The final reference panel consisted of 98 individuals, and
1,328, 536 SNP‟s at 0% missingness.
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Figure 6.4 Schema of combined analysis quality control pipeline.
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Imputation of genotypes from the Ashkenazi reference panel

The AJ reference panel was then used as a training set to impute missing genotypes for
the combined NY1-6 and TA1 datasets using BEAGLE (Browning, 2007). SNP‟s that
were either low in frequency (MAF <0.01) or had a poor imputation quality score
(r2<0.9) were excluded (see Figure 6.4). The final combined dataset of genotyped and
imputed SNP‟s contained 1,068,161 SNP‟s across 3,211 AJ samples (935 cases and 2,276
controls).

Association mapping of CD in Ashkenazi Jews

Prior to performing association mapping, non-AJ samples as determined by PCA analysis
(see above) were excluded from the sample (n=251). In addition, to control for batch
effects across the seven cohorts, markers that were association p<10-5 in a pairwise
cohort-cohort association (stratified by CD case status), were also excluded (n=7,227),
Figure 6.4. The final filtered dataset used for association mapping comprised 1,060,934
genotyped and imputed markers across 2,960 individuals, divided into three groups
according to AJ ancestry (see above).

For association mapping, we first built a kinship matrix of pairwise identity-by-state
metrics based the high-density markers for the entire sample, which was incorporated
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Figure 6.5 Association mapping of Crohn Disease in Ashekenazi Jews. (A) QQ-plots of the 100%, 75%
and 50% AJ ancestry groups (groups 1,2 and 3, respectively). The number of individuals in each group is
shown and the inflation factor for the p-value distribution is given. In the case of group 3, the p-values were
genomic control adjusted for overinflation. (B) A manhattan plot (left) and qq-plot (right) of the combined
association score from all three groups. (C) The same as B, but with 526 markers around the region of
NOD2 signal on chromosome 16 removed before association mapping. The qq-plot shows the p-value
distribution before (gray) and after (black) NOD2 removal and the inflation factor is for the latter.
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into the mixed model for association mapping for the three groups (Kang, 2010). The pvalues were combined across the three groups using METAL, which takes direction of
effect into account and weights the groups by sample size (Willer, 2008). Figure 6.5(A)
shows the qq-plots for 100%, 75% and 50% AJ ancestry groups (groups 1,2 and 3,
respectively). In the case of group 3, the p-values were quite overinflated (λ=1.14) and
were corrected by genomic control to approximate normality (Devlin, 1999).

Observation of positive controls in Ashkenazi Jews

Figure 6.5(B) shown the combined score from all three groups, and as positive controls,
we observe two genomic regions exceeding our genome wide significance threshold of
5x10-8. Top SNPs are in known loci for Crohn Disease, NOD2 (16q12; rs2076756;
p<2.32x10-20) and IL23R (1p31; rs11209026; p<9.42x10-9) (Barrett, 2008). In addition,
we see 6 other signals for known loci p<10-4; ATG16L1 (2q37; rs2241880; p<2.88x10-6),
IL3 (5q31; rs3091338; p<4.86x10-5), ZNF365(10q21; rs1076165; p<9.31x10-6),
intergenic region >300kb upstream of PTGER4 (5p13.1; rs9292777; 6.92x10-5), JAK2
(9p24.1;rs2230724; p<8.11x10-5) and NKX2-3 (10q24.2; rs11190141; 9.8x10-5) (Barrett,
2008)(Parkes, 2007). Finally we observed an interesting novel region approaching
genome wide significance on chromosome 8q24 rs2922500 (chr8:134,676,639;
p<8.36x10-8). The SNP is in an intergenic region and resides in a known in large deletion
spanning chr8:134675707-134680644.
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Haplotypic fine mapping of the NOD2 locus

We performed haplotypic mapping on the broad peak at the NOD2. Haplotype mapping
has been previously described in Chapter 2. Briefly, common shared long-range
haplotypes were detected via pair-wise IBD genetic segment matching between all
individuals in the pedigree using the GERMLINE software (Gusev, 2009). The IBD
segments were at least 3cM in length and allowed for up to 1% mismatching due to
genotyping error. IBD segments were then clustered to groups of similar haplotypes,
with >500kb overlapping sequence and sharing >99% sequence identity, as described in
detail previously (Kenny, 2009). Clusters of shared haplotypes were then independently
mapped to Crohn‟s disease which identified a single strong mapping cluster, where the
specific sharing boundaries of the 253kb haplotype mapped to a sub-region (chr16:48.148.4) of the Crohn‟s GWAS signal peak, ~1MB upstream of the top SNP in the region.
This novel "CD haplotype" (rs1420682 to rs11076503) is unique to a group of 396
individuals (carrier frequency 0.13), is strongly associated to CD (p<8.1x10-17), and has
an odds ratio of 1.47. A logistical regression of CD with the CD haplotype as a covariate
has little effect on the signal for the top NOD2 SNP (p<1.45x10-17). Likewise, a logistical
regression of CD with the top NOD2 SNP (rs2076756) as a covariate has little effect on
the CD haplotype (p<3.45x10-15), indicating that the two signals are independently
associated to CD. A genome-wide scan of Crohn‟s disease using both the CD haplotype
and rs2076756 revealed no remaining genome-wide significant signal in the region
(p<10-4), indicating that rs2076756 and the CD haplotype likely capture the full signal in
the region.
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Discussion
We describe a GWAS for Crohn‟s disease across seven Ashkenazi Jewish cohorts using a
combined analysis strategy and a population specific reference panel for imputation. The
analysis yielded 8 positive controls, 2 of which were genome-wide significant, and an
interesting novel region of borderline significance on chromosome 8q24.

More

importantly, haplotypic fine mapping of the strong signal peak on chromosome 16
revealed a novel haplotype ~1MB upstream of the signal that was independent on the top
SNP.
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Chapter 7 : Discussion

Implementing improved analytical strategies for founder populations

The goal of this thesis was to explore the opportunities for analyzing founder populations
to detect causal variants affecting complex disease. The idea was to leverage the unique
features of such populations for exploring genetic variations, in particular rare variations,
while overcoming the technical challenges inherent to their genetic architecture. We first
tested specialized strategies in a small, highly related, founder population. We then
demonstrated the extensibility of these approaches by successfully applying them in a
larger, less extreme, founder population.

Improved methodology for genotypic mapping

GWAS of samples containing extensive relatedness, which is usually the case for founder
populations,

have

been

traditionally

analyzed

using

family-based

methods

(Gudmundsson, 2007, Ober, 2001, Lowe, 2009). However, extensive analysis at a single
locus level has previously shown that family-based tests have lower power than
population-based methods, such as mixed-models, in the presence multiple levels of
relatedness (Yu, 2006), and we have observed this on Kosrae (Lowe, 2009). The
statistical advantage of mixed-models comes at the cost of higher model complexity,
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resulting in a lack, until recently, of mixed model methods capable of handling largescale human datasets in a computationally efficient manner.

Here we have demonstrated the improved power for mixed models in the context of the
extensive, multi-generational relatedness found on the Island of Kosrae. We focused
specifically on a range of p-values not yet explored and showed that mixed models gave a
>2-fold boost in power over other methods. Importantly for the reduction of false
positives, the test statistic produced is uniformly distributed, with no artificial
overdispersion of the p-value. The improvement in power is due in part to the utilization
of variation both within and between samples (captured in the kinship matrix) and also
the ability to include all samples in the analysis. Our empirical results on Kosrae show
similar power to like-sized outbred populations and support the use of mixed-models for
association in founder populations.

Novel methodology for haplotypic mapping

Much of the work for association analysis has been focused on the effects of single SNPs.
We provide a more extensive approach that considers long range haplotypes, identicalby-descent, across multiple samples, as genetic markers. Such recently arising haplotypes
are likely to carry rare mutations, which are the focus of sequencing endeavors (see
below). As proof of the pudding, we provide examples for three novel signals, mapped by
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association to long range haplotypes on Kosrae, with two casual mutations confirmed by
sequencing.

This approach was aided by a high degree of relatedness and founder effects on Kosrae
that resulted in abundant, long haplotypes in our study population (Bonnen, 2006).
However, recently, tracks of relatedness in regions of the genome have also been seen in
less extreme founder population (Kong, 2008), and even in apparently unrelated
populations (Frazer, 2007). We therefore tested the haplotype mapping approach in a
canonical founder population, with less extreme founding effects than are seen on
Kosrea, the Ashkenazi Jewish population. We demonstrated the extensibility of our
method in this less founder population by mapping a novel haplotype for Crohn‟s disease.

A key advantage of haplotypic mapping compared to genotypic mapping, is the
additional positional information, where the physical haplotype boundaries, as well as the
specific carriers, are explicitly identified – a useful roadmap of follow up sequencing. We
also demonstrated in three of the cases that our method can be used to dissect multiple
signals at the same locus. In addition, since the long shared haplotypes were constructed
from SNP-chip data, this approach can complement a traditional association mapping
method. However, the method is limited to resolving very long haplotypes < 20
generations old. If a causal mutation arose more distantly and surrounding haplotypes are
too short the method will not have any mapping power.
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New biological insights

Overall, a GWAS, using mixed models, of 30 metabolic traits on Kosrae yielded 13
positive controls and 4 novel loci for height, haemoglobin A1C, uric acid and plasma
plant sterol levels, 3 of the latter being refined by haplotype mapping. The same
approaches applied in an Ashkenazi Jewish cohort for a single trait, produced two
positive controls, a novel hit region and a novel independent associated haplotype at one
of the positive control loci.

Effect sizes in founder populations

To examine the genetics of common traits on Kosrae as compared to outbred populations,
we assessed the effect sizes observed on Kosrae for known loci discovered in studies
using outbred, mainly Caucasian populations. We showed that some variants that are
associated to traits in other populations do not replicate on Kosrae, due to bottleneck
effects rather than lack of power. On the other hand, observed associations show strong
effects and statistical support for a cohort of this size (with the caveat that the number of
markers we were able to compare is small). While this empirical observation is open to
interpretation, and somewhat anecdotal, it does indicate the benefit of increased genetic
and environmental homogeneity for variant discovery.
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Detection of rare variation

Using the haplotypic mapping method, it was possible to detect a relatively rare (minor
allele frequency < 1%) causal genetic variants. Expanding the search for associated
alleles to variants that are rare in the general population provides another piece of the
heritable component of disease, with multiple gene sequencing studies implicating such
variants with moderate to high penetrance (Fearnhead, 2004, Cohen, 2004, Kotowski,
2006, Romeo, 2007, Marini, 2008). The new era of high throughput sequencing returns
the emphasis to rare variation, playing to the strength of isolated communities.

Limitations of founder populations studies

Replication of results in the hands of a different researcher is a cornerstone of good
science. Genetic association signals for alleles that are common and shared across
populations and continents have been successfully replicated. In the Kosraen study, such
replication is expected to be more challenging, especially for rare, newly arisen variants,
as some variants are expected to be limited to Pacific islanders or East Asians that are
under-represented in large association studies. We rely on increased participation of these
groups in such studies, facilitating replication in the future. Furthermore, as linkage
studies have succeeded to establish over the last two decades, there are multiple options
to support a genetic effect of a variant, even when it is a family-specific mutation. These
criteria should hold for the “extended family” of Kosrae. Mutations can be supported by
118

evidence from annotation, other variants in the same gene, or pathways with observed
enrichment of causal variation and functional follow-up in the lab.

Imputation of unobserved genotypes of common alleles has been previously used in
general, outbred populations. This approach relies on the ancient shared origin of an
imputed sample and reference individuals, forfeiting the option to impute the lowfrequency alleles that have arisen since their common ancestor. The strategy requires the
availability of a densely genotyped reference panel, such as the HapMap project (Frazer,
2007). However, there is reduced portability of this approach to populations that are,
compared to available reference panels, genetically distinct, such as founder populations.
This leads to a reduction in imputation accuracy, and a consequent reduction in statistical
power for imputation based association mapping. We have observed poor imputation
power for both founder populations used in this study, especially on Kosrae. This
problem is expected to be somewhat alleviated as more populations are added to the
existing referencing panels, such as the Jewish HapMap (pers.comm. Harry Ostrer). In
addition, the abundance of homozygosity (Morrow, 2008) and long-range haplotypes
(Kong, 2008) found in population isolates will facilitate the next generation of tools for
the detection of rare disease-associated haplotypes. For example, methods for imputation
based on IBD segments are expected to capture many recently arising mutations, thus
leveraging the power of sequencing technologies to observe new variation.
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Future directions

Hand in hand with the explosion of genotype data in the past few years, many exciting
technical advances have been made in the area of sequencing. Recently, there has been a
fundamental shift away from traditional Sanger sequencing towards so-called “nextgeneration sequencing” (NGS) technologies for genome analysis. These newer
technologies constitute various strategies that rely on a combination of template
preparation, sequencing and imaging, and genome alignment and assembly methods
(Metzker, 2010). The production of large numbers of low-cost reads make the NGS
platforms useful for many applications, such as cataloguing transcriptomes (RNAsequencing) or epigenetic marks (ChIP-sequencing, Methyl-sequencing), and

re-

sequencing target areas of a genome. The broadest application of NGS is in the
sequencing of human whole-genomes to enhance our understanding of how genetic
differences affect health and disease.

Many of the initial whole-genome sequencing studies have focused on proof-oftechnology, and presently, high-quality personal genomes exist from representatives of
the major continental groups (Wheeler, 2008, Ahn, 2009, Bentley, 2008, Kim, 2009,
Levy, 2007, McKernan, 2009, Wang, 2008). The major advance offered by NGS is the
ability to produce enormous volume of data cheaply, the lowest published cost being
~$5K for a whole human genome (Drmanac, 2010), down from $1 in 2004 to a small
fraction of a cent (<$0.000002) per base pair today.
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Current approaches for sequence-based mapping of human disease included wholeexome capture in a small number of individuals. This approach has been successful in
identifying causal variants in monogenic disease cases (Ng, 2010). However, such studies
ignore non-coding regions and do not yet scale to large populations (Galvan, 2010). For
complex traits, a popular approach is the targeted re-sequencing of candidate loci under
local signal peaks detected in GWAS across many individual (Cohen, 2004). However,
this strategy scales poorly for multiple traits and across a large number of loci and
pursuing such a strategy genome-wide is still resource intensive, despite a considerable
drop in sequencing costs. We suggest an alternative paradigm for population-based
sequencing that plays to the strengths of a small, extreme isolate population, such as
Kosrae.

A population-based paradigm for sequencing in founder populations

Our strategy leverages the current multi-trait GWAS data and the inherent relatedness of
the cohort with the resultant enrichment of IBD long genetic segments on the island. We
devise an approach to sequence a small number of individuals, forming a population
specific reference panel of the island. In conjunction, we can use the GWAS SNP‟s to
construct a genomewide, population-wide catalogue of long segments that are IBD across
individuals. Finally, we can propagate any reference panel variants to non-sequenced
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individuals through imputation based on the IBD segments for mapping across multiple
traits.

Our intial estimates show that sequencing ~80 individuals selected for most IBD sharing
on Kosrae will capture > 80% of the total variation on the island. In other words, a
modest 0.25TB sized reference panel has the potential to yield >7TB of imputed
sequence. This means that in Kosrae, we can cover the entire genome sequence with
resources that are sufficient for only targeted, candidate gene sequencing of similar
sample sizes in most populations, as they lack these characteristics of isolation. Analysis
of this genetic data in conjunction with phenotypic data in Kosrae holds the potential
pinpoint novel causal variants for multiple traits.

Conclusion

This study of founder populations has highlighted the usefulness of understanding the
population-genetic properties of a particular study population for recognizing the features
and limitations of disease mapping in that population. As the field of human genetics
moves forward to explore new and expanded sources of variation, models of these
population-genetic features offers a context with which to interpret the data. Because the
full genetic history of the human population is unknown, population-genetic models can
be used instead to generate plausible theories. Such models begin from the perspective
that the factors that affect the genealogical descent of a disease mutation, such as
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bottlenecks, migrations and the recombination landscape, ultimately affect the
distribution of the variant across contemporary individuals and populations. Thus, the
properties of risk variants simulated under such models can be used to evaluate strategies
for detecting them. Further, the models themselves will be calibrated and improved as
deeper and richer human genetic data becomes available.
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